[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 928
1. Naik VR, Jaafar H, Seng CE: Lymphatic channel density in colorectal adenocarcinoma. Indian J Pathol Microbiol; 2010 Jan-Mar;53(1):12-4
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic channel density in colorectal adenocarcinoma.
  • AIMS: The purpose of this study was to count the number of lymphatic channels present in colorectal adenocarcinoma and correlate it with site, size, and stage of tumor, lymph node metastasis.
  • MATERIAL AND METHODS: A total of 29 cases of colorectal carcinomas were retrieved from the archives of the pathology department, School of Medical Sciences.
  • RESULTS: The highest density of lymphatic channels in colorectal carcinoma was counted after identifying the appropriate "hot spot".
  • CONCLUSION: In this study no significant association was seen between lymphatic channel density and site, size, stage and lymph node metastasis in colorectal carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Lymphatic Vessels / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090214.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


2. Katkoori VR, Jia X, Shanmugam C, Wan W, Meleth S, Bumpers H, Grizzle WE, Manne U: Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res; 2009 Apr 01;15(7):2406-16
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma.
  • PURPOSE: Several studies have examined the prognostic value of the codon 72 polymorphism of the p53 gene in colorectal adenocarcinoma, but none have addressed patient race/ethnicity.
  • Therefore, this study assessed the prognostic value of this polymorphism in African American and Caucasian colorectal adenocarcinoma patients separately.
  • EXPERIMENTAL DESIGN: Colorectal adenocarcinomas from 137 African Americans and 236 non-Hispanic Caucasians were assessed for p53 mutations and genotyped for the codon 72 polymorphism.
  • P = 0.886) and risk of death due to colorectal adenocarcinoma (hazard ratio, 2.15; 95% confidence interval, 1.02-4.53 versus hazard ratio, 1.60; 95% confidence interval, 0.69-3.18) than those with the phenotype Arg/Arg or Arg/Pro.
  • CONCLUSIONS: The higher frequency of the Pro/Pro phenotype of p53 in African American patients with colorectal adenocarcinoma is associated with an increased incidence of p53 mutations, with advanced tumor stage, and with short survival.
  • [MeSH-major] Adenocarcinoma / ethnology. African Americans / genetics. Colorectal Neoplasms / ethnology. European Continental Ancestry Group / genetics. Genes, p53. Polymorphism, Single Nucleotide

  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827855493 for PMID:19339276 [PharmGKB] .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1991 Dec 25;19(24):6969 [1684850.001]
  • [Cites] Nucleic Acids Res. 1991 Sep 11;19(17):4799 [1679931.001]
  • [Cites] Oncogene. 1993 Jun;8(6):1703-5 [8502490.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3819-26 [8508350.001]
  • [Cites] Am J Hum Genet. 1993 Sep;53(3):752-9 [8352280.001]
  • [Cites] Gastroenterology. 1994 Jan;106(1):42-8 [8276207.001]
  • [Cites] Int J Epidemiol. 1994 Feb;23(1):50-7 [8194924.001]
  • [Cites] Science. 1994 Jul 15;265(5170):334-5 [8023155.001]
  • [Cites] Science. 1994 Jul 15;265(5170):346-55 [8023157.001]
  • [Cites] Lancet. 1994 Jul 23;344(8917):233-4 [7913159.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4855-78 [8069852.001]
  • [Cites] Am J Gastroenterol. 1995 May;90(5):758-60 [7733083.001]
  • [Cites] Diagn Mol Pathol. 1995 Mar;4(1):54-8 [7735557.001]
  • [Cites] Carcinogenesis. 1995 Jul;16(7):1461-4 [7614678.001]
  • [Cites] Carcinogenesis. 1995 Sep;16(9):2205-8 [7554076.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 15;87(22):1686-93 [7473817.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Sep;14(1):71-5 [8527388.001]
  • [Cites] Nat Med. 1996 Jul;2(7):811-4 [8673929.001]
  • [Cites] Nutr Cancer. 1996;25(2):129-35 [8710682.001]
  • [Cites] Am J Public Health. 1996 Dec;86(12):1794-7 [9003140.001]
  • [Cites] Nutr Cancer. 1997;28(1):52-62 [9200151.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):346-58 [9221816.001]
  • [Cites] Oncogene. 1998 Apr 2;16(13):1671-9 [9582015.001]
  • [Cites] Biotechniques. 1999 Feb;26(2):198-200 [10023524.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):593-9 [10080604.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1670-6 [10223559.001]
  • [Cites] Eur J Cancer. 1999 Feb;35(2):226-30 [10448264.001]
  • [Cites] Mol Cell Probes. 1999 Oct;13(5):393-5 [10508562.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Dec;130(12):728-32 [15365822.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):529-35 [15548361.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2502-9 [15814626.001]
  • [Cites] Cancer. 2005 May 15;103(10):2163-70 [15816050.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):443-51 [10690522.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1031-7 [10741731.001]
  • [Cites] Nat Genet. 2000 May;25(1):47-54 [10802655.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2999-3005 [10955777.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6875-7 [11156383.001]
  • [Cites] J Clin Epidemiol. 2001 Apr;54(4):359-66 [11297886.001]
  • [Cites] Leuk Lymphoma. 2001 May;41(5-6):655-8 [11378583.001]
  • [Cites] Carcinogenesis. 2001 Nov;22(11):1831-5 [11698346.001]
  • [Cites] J Natl Cancer Inst. 2002 May 1;94(9):681-90 [11983757.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1192-5 [12006537.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1684-8 [12496062.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 1;140(1):23-30 [12550754.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):196-9 [14639602.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):66-76 [15221990.001]
  • [Cites] Mol Cell Biol. 1987 Feb;7(2):961-3 [3547088.001]
  • [Cites] Oncogene. 1991 Sep;6(9):1691-2 [1923533.001]
  • [Cites] J Biol Chem. 2005 Jun 24;280(25):24245-51 [15851479.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2179-87 [16682737.001]
  • [Cites] Cancer Biomark. 2007;3(6):301-13 [18048968.001]
  • [Cites] Dis Esophagus. 2008;21(2):139-43 [18269649.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Genet Mol Res. 2008;7(1):207-16 [18393224.001]
  • [Cites] Gene. 1988 Oct 30;70(2):245-52 [2905688.001]
  • [Cites] Nucleic Acids Res. 1991 Sep 11;19(17):4796 [1716362.001]
  • [Cites] Nucleic Acids Res. 1991 Dec 25;19(24):6977 [1762941.001]
  • (PMID = 19339276.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U54 CA118623; United States / NCI NIH HHS / CA / U54 CA118948; United States / NCI NIH HHS / CA / R01 CA098932; United States / NCI NIH HHS / CA / R01-CA98932-01; United States / NCI NIH HHS / CA / U54-CA118948
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon
  • [Other-IDs] NLM/ NIHMS452892; NLM/ PMC3635077
  •  go-up   go-down


3. Malhotra P, Kochhar R, Vaiphei K, Wig JD, Mahmood S: Aberrant promoter methylation of p16 in colorectal adenocarcinoma in North Indian patients. World J Gastrointest Oncol; 2010 Jul 15;2(7):295-303

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant promoter methylation of p16 in colorectal adenocarcinoma in North Indian patients.
  • AIM: To investigate p16 gene methylation and its expression in 30 patients with sporadic colorectal adenocarcinoma in a North Indian population.
  • METHODS: Methylation specific polymerase chain reaction was used to detect p16 gene methylation and immunohistochemistry was used to study the p16 expression in 30 sporadic colorectal tumors as well as adjoining and normal tissue specimens.
  • Immunohistochemistry showed expression of p16 protein in 26 (86.6%) colorectal tumors whereas complete loss of expression was seen in 4 (13.3%) and reduced expression was observed in 12 (40%) tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160660.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2998854
  • [Keywords] NOTNLM ; Colorectal cancer / Immunohistochemistry / Methylation / Methylation specific polymerase chain reaction / p16
  •  go-up   go-down


Advertisement
4. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T, Sekine I: Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol; 2005 Aug;58(8):833-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors.
  • AIMS: To examine the relation between p-STAT3 (activated form of STAT3) expression and clinicopathological factors in human colorectal adenocarcinoma and adenoma.
  • METHODS: Immunohistochemical analyses were carried out on tissues from 44 colorectal adenomas and 95 colorectal adenocarcinomas, comprising 18 intramucosal carcinomas and 77 invasive carcinomas.
  • Only eight of the 44 adenomas showed immunopositivity for p-STAT3, resulting in a significant difference between total adenocarcinomas and adenomas (p < 0.001).
  • Among the 95 cases of colorectal adenocarcinoma, p-STAT3 immunoreactivity was significantly correlated with the depth of tumour invasion (p < 0.05), venous invasion (p < 0.05), lymph node metastasis (p < 0.05), and increasing stages of the Dukes' classification (p < 0.01).
  • Expression of p-STAT3 was detected by Western blot analysis in two different cultured human colorectal carcinoma cell lines and six colon carcinoma tissue samples obtained at surgery.
  • These findings suggest that p-STAT3 expression is an important factor related to carcinogenesis and/or tumour invasion of colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. DNA-Binding Proteins / metabolism. Trans-Activators / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1994 Apr 15;73(8):2076-82 [8156513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):4806-10 [7545930.001]
  • [Cites] Science. 1994 Jun 3;264(5164):1415-21 [8197455.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1285-90 [7992833.001]
  • [Cites] Cancer Lett. 2000 Apr 3;151(1):31-8 [10766420.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2489-95 [10851047.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2607-11 [10851059.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):67-73 [11006034.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):25-32 [11141475.001]
  • [Cites] Dig Dis Sci. 2001 Feb;46(2):230-41 [11281168.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2000-8 [11960372.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1139-42 [11994401.001]
  • [Cites] Cancer. 2002 May 1;94(9):2393-400 [12015764.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7001-10 [12370822.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1517-27 [12629515.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):891-905 [12949733.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7809-18 [14586407.001]
  • [Cites] J Cell Physiol. 2004 Feb;198(2):209-22 [14603523.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):15114-23 [14701810.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3550-60 [15116091.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1569-73 [15162527.001]
  • [Cites] Br J Surg. 1976 May;63(5):384-8 [1268479.001]
  • [Cites] Histopathology. 1981 Mar;5(2):141-63 [7216178.001]
  • [Cites] Cancer. 1986 Sep 15;58(6):1340-5 [3742458.001]
  • [Cites] Science. 1994 Apr 1;264(5155):95-8 [8140422.001]
  • [Cites] Cytokine. 1995 Feb;7(2):118-29 [7780031.001]
  • [Cites] Nature. 1995 Oct 19;377(6550):591-4 [7566171.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3651-8 [8670868.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3801-4 [9108058.001]
  • [Cites] Jpn J Cancer Res. 1997 Jun;88(6):600-4 [9263538.001]
  • [Cites] Science. 1997 Sep 12;277(5332):1630-5 [9287210.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):433-42 [9711905.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):326-30 [9766567.001]
  • [Cites] J Leukoc Biol. 1998 Nov;64(5):675-80 [9823774.001]
  • [Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]
  • [Cites] Jpn J Cancer Res. 1998 Dec;89(12):1267-75 [10081487.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] J Clin Pathol. 1949 May;2(2):95-8 [16810849.001]
  • (PMID = 16049285.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Trans-Activators
  • [Other-IDs] NLM/ PMC1770863
  •  go-up   go-down


5. Kontos CK, Papadopoulos IN, Fragoulis EG, Scorilas A: Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. Br J Cancer; 2010 Apr 27;102(9):1384-90
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma.
  • The aim of this study was to investigate the mRNA expression levels of the DDC gene and to evaluate its clinical utility in tissues with colorectal adenocarcinoma.
  • METHODS: Total RNA was isolated from colorectal adenocarcinoma tissues of 95 patients.
  • RESULTS: DDC mRNA expression varied remarkably among colorectal tumours examined in this study.
  • CONCLUSIONS: The results of the study suggest that DDC mRNA expression may be regarded as a novel potential tissue biomarker in colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Dopa Decarboxylase / genetics. Gene Expression Regulation, Neoplastic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood Cells Mol Dis. 2009 Jan-Feb;42(1):92-8 [19041269.001]
  • [Cites] Neurochem Res. 2009 Jun;34(6):1089-100 [19005753.001]
  • [Cites] Nat Rev Cancer. 2009 Jul;9(7):489-99 [19536109.001]
  • [Cites] Mol Cell Biochem. 1990 May 10;94(2):147-56 [2374548.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6068-74 [2168288.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2161-5 [2006153.001]
  • [Cites] Biochemistry. 1992 Mar 3;31(8):2229-38 [1540578.001]
  • [Cites] Br J Cancer. 1992 Jul;66(1):148-54 [1379057.001]
  • [Cites] J Natl Cancer Inst. 1992 Oct 21;84(20):1572-5 [1404450.001]
  • [Cites] Biochemistry. 1992 Nov 24;31(46):11546-50 [1445888.001]
  • [Cites] Lancet. 1992 Dec 5;340(8832):1369-73 [1360088.001]
  • [Cites] N Engl J Med. 1994 Jul 28;331(4):213-21 [8015568.001]
  • [Cites] Biochem Pharmacol. 1995 Sep 7;50(6):845-50 [7575647.001]
  • [Cites] J Neurochem. 1995 Dec;65(6):2409-16 [7595534.001]
  • [Cites] Neurochem Res. 1996 Sep;21(9):1075-87 [8897471.001]
  • [Cites] N Engl J Med. 1996 Dec 5;335(23):1727-32 [8929264.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):427-33 [9469325.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1180-7 [9609754.001]
  • [Cites] Dis Colon Rectum. 1998 Jun;41(6):755-60 [9645744.001]
  • [Cites] Br J Cancer. 1999 Jan;79(2):191-203 [9888457.001]
  • [Cites] Clin Biochem. 2008 Oct;41(14-15):1140-9 [18586020.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Neuroimmunol. 2009 Nov 30;216(1-2):51-8 [19800137.001]
  • [Cites] Eur J Cancer. 2010 Mar;46(4):765-81 [20116997.001]
  • [Cites] Biochem Pharmacol. 1999 Jun 15;57(12):1341-4 [10353253.001]
  • [Cites] Am J Pathol. 1999 Jul;155(1):17-21 [10393831.001]
  • [Cites] Neurochem Res. 2004 Oct;29(10):1817-23 [15532536.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7252-9 [15534099.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):434-44 [15668707.001]
  • [Cites] J Gastrointest Surg. 2005 Mar;9(3):336-42 [15749593.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2606-11 [15814640.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9901-6 [15998737.001]
  • [Cites] Neurochem Res. 2005 May;30(5):641-9 [16176068.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(14):2060-70 [16125380.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7518-28 [16172461.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2005 Nov;372(3):228-35 [16247607.001]
  • [Cites] J Histochem Cytochem. 2006 Aug;54(8):863-75 [16517981.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5313-27 [17060676.001]
  • [Cites] Hum Pathol. 2007 Jan;38(1):161-70 [16997353.001]
  • [Cites] Mol Cancer. 2007;6:38 [17553164.001]
  • [Cites] Dig Dis Sci. 2008 May;53(5):1289-96 [17934851.001]
  • [Cites] Gut. 2008 Jul;57(7):941-50 [18364437.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Dig Surg. 2000;17(3):209-15 [10867451.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4365-72 [11106255.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Int J Cancer. 2002 Jan 1;97(1):72-81 [11774246.001]
  • [Cites] Methods. 2001 Dec;25(4):386-401 [11846608.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Br J Cancer. 2002 Sep 9;87(6):630-4 [12237773.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]
  • [Cites] Neurochem Res. 2003 Jun;28(6):797-803 [12718431.001]
  • [Cites] Biochem J. 2003 Oct 15;375(Pt 2):373-83 [12864730.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):529-36 [14752076.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):665-71 [14760382.001]
  • [Cites] Diagn Mol Pathol. 2004 Sep;13(3):135-43 [15322424.001]
  • [Cites] Proc Natl Acad Sci U S A. 1972 Feb;69(2):343-7 [4536745.001]
  • [Cites] Endocrinology. 1983 Apr;112(4):1524-9 [6339207.001]
  • [Cites] Biochemistry. 1983 Dec 20;22(26):6058-63 [6661425.001]
  • [Cites] Cancer. 1986 May 1;57(9):1866-70 [3485470.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):4078-82 [3383200.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Nov 15;164(3):1024-30 [2590185.001]
  • [CommentIn] Br J Cancer. 2010 Oct 26;103(9):1475-6 [20859286.001]
  • (PMID = 20424616.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 4.1.1.- / Dopa Decarboxylase
  • [Other-IDs] NLM/ PMC2865762
  •  go-up   go-down


6. Wang MS, Pan Y, Liu N, Guo C, Hong L, Fan D: Overexpression of DARPP-32 in colorectal adenocarcinoma. Int J Clin Pract; 2005 Jan;59(1):58-61
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of DARPP-32 in colorectal adenocarcinoma.
  • Our aim is to investigate the expression of DARPP-32 protein in colorectal adenocarcinoma.
  • DARPP-32 was specifically localised in colorectal epithelium.
  • The expression of DARPP-32 in colorectal adenocarcinoma tissues 33/42, 78.57% was higher than that in normal colon epithelial tissues (31/60, 51.67%, p <0.05).
  • There was no significant relationship between the expression of DARPP-32 and the differentiation, metastasis and Dukes' stage of colorectal adenocarcinoma (p >0.05).
  • Both DARPP-32 and its truncated isoform t-DARPP were overexpressed in colorectal adenocarcinoma (t=2.306, p=0.028), while t-DARPP was more frequently detected.
  • These results showed that DARPP-32 may play an important role in the regulation of normal colorectal epithelial biology and carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Nerve Tissue Proteins / metabolism. Phosphoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15707466.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dopamine and cAMP-Regulated Phosphoprotein 32; 0 / Nerve Tissue Proteins; 0 / Phosphoproteins
  •  go-up   go-down


7. Murad JC, Ribeiro U Jr, Safatle-Ribeiro AV, Parra E, Rawet V, Corbett CE, Ferreira VA, Pugliese V, Saad WA, Habr-Gama A, Gama-Rodrigues J: Evaluation of molecular markers in hepatic metastasis of colorectal adenocarcinoma. Hepatogastroenterology; 2007 Jun;54(76):1029-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of molecular markers in hepatic metastasis of colorectal adenocarcinoma.
  • BACKGROUND/AIMS: There were 49 patients studied, coming from The Liver Unit at the "Hospital das Clinicas da Faculdade de Medicina da USP (N=41) and from "Prof. Dr.
  • Angelita Habr-Gama and Joaquim Gama-Rodrigues Surgery Institute", SP (N=8); all of which had hepatic metastasis of colorectal adenocarcinoma, with no evidence of concurrent metastasis in any other organs and were submitted to surgical treatment, during the period of 1992 to 2002, with the aim of analyzing the immunoexpression of the p53, ki-67, p16 and molecular markers in order to relate the disease-free period with the prognosis.
  • CONCLUSIONS: Molcular markers may be useful to evaluate hepatic metastasis of colorectal Adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Colorectal Neoplasms / pathology. Liver Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629032.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


8. Lam AK, Saleh S, Smith RA, Ho YH: Quantitative analysis of survivin in colorectal adenocarcinoma: increased expression and correlation with telomerase activity. Hum Pathol; 2008 Aug;39(8):1229-33
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of survivin in colorectal adenocarcinoma: increased expression and correlation with telomerase activity.
  • The aims of the present study are to quantitatively analyze survivin expression, its clinicopathologic roles, and correlation with telomerase activity in a large cohort of patients with colorectal adenocarcinoma.
  • Real-time polymerase chain reaction was used to quantitate expression level of survivin messenger RNA and human telomerase reverse transcriptase messenger RNA (telomerase activity) in 51 patients with colorectal adenocarcinomas.
  • The level of expression of survivin was significantly correlated with the level of human telomerase reverse transcriptase expression (P = .008) and size of the colorectal adenocarcinomas (P = .004).
  • Survival of the patients with colorectal adenocarcinoma was associated with the TNM stages (P = .001) and not with the level of expression of survivin.
  • Thus, survivin activity was altered in colorectal adenocarcinoma.
  • The high prevalence of survivin expression and correlation with telomerase activity are important factors for consideration in gene targeting therapy for colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemistry. Colorectal Neoplasms / chemistry. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Telomerase / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18547619.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


9. Lam AK, Ong K, Giv MJ, Ho YH: p16 expression in colorectal adenocarcinoma: marker of aggressiveness and morphological types. Pathology; 2008 Oct;40(6):580-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in colorectal adenocarcinoma: marker of aggressiveness and morphological types.
  • AIM: The aim of the present study was to investigate the clinicopathological roles of p16 expression in a large cohort of patients with colorectal adenocarcinoma with tight methodology and close follow-up.
  • METHODS: p16 protein expression was investigated in 194 patients (102 men, 92 women) with colorectal adenocarcinomas by immunohistochemistry.
  • RESULTS: p16 protein was detected in 80% (155 of 194) of patients with colorectal carcinoma.
  • The p16 protein was more often detected in male patients with colorectal cancers (86% versus 73%, p = 0.03).
  • p16 protein expression was more often seen in carcinomas in the rectum, sigmoid and descending colon compared with more proximal colon (90% versus 61%, p = 0.001).
  • The p16 protein was more often detected in well or moderately differentiated colorectal adenocarcinoma than poorly differentiated colorectal adenocarcinoma (84% versus 63%, p = 0.009).
  • The level of expression of p16 protein is related to the lymph nodal status (p = 0.004) and the TNM staging of the colorectal carcinoma (p = 0.008).
  • CONCLUSION: p16 protein expression was common in colorectal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pathology. 2008 Dec;40(7):734. Giv, Mahmound Jafari [corrected to Giv, Mahmoud Jafari]
  • (PMID = 18752124.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


10. Vougas K, Gaitanarou E, Marinos E, Kittas C, Voloudakis-Baltatzis IE: Two-dimensional electrophoresis and immunohistochemical study of calreticulin in colorectal adenocarcinoma and mirror biopsies. J BUON; 2008 Jan-Mar;13(1):101-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-dimensional electrophoresis and immunohistochemical study of calreticulin in colorectal adenocarcinoma and mirror biopsies.
  • PURPOSE: The purpose of this study was to analyse the polypeptide patterns of colorectal adenocarcinomas and mirror biopsies and to investigate the expression of calreticulin and the relationship of this chaperon to colon cancer.
  • MATERIALS AND METHODS: The investigation was carried out on 21 adenocarcinomas and 21 mirror biopsies using high-resolution two-dimensional (2D) electrophoresis and immunohistochemical PAP method.
  • RESULTS: 2D electrophoresis revealed several polypeptide patterns that were shown to be upregulated in colorectal adenocarcinomas compared to their mirror biopsies.
  • One polypeptide spot being upregulated in colorectal adenocarcinoma, turned out to be calreticulin.
  • CONCLUSION: Calreticulin was found overexpressed in colon cancer tissues as compared to the corresponding mirror biopsy tissues.
  • [MeSH-major] Adenocarcinoma / chemistry. Calreticulin / analysis. Colorectal Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404795.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Calreticulin
  •  go-up   go-down


11. Lam AK, Ong K, Ho YH: hTERT expression in colorectal adenocarcinoma: correlations with p21, p53 expressions and clinicopathological features. Int J Colorectal Dis; 2008 Jun;23(6):587-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] hTERT expression in colorectal adenocarcinoma: correlations with p21, p53 expressions and clinicopathological features.
  • BACKGROUND: The clinicopathological roles and relationships of hTERT, p21 and p53 proteins have not been studied in depth in colorectal cancer.
  • The aim of the present study is to investigate the clinicopathological roles of expression of hTERT protein expression and its relationship with the expression of p21 and p53 proteins in a large cohort of patients with colorectal adenocarcinoma.
  • MATERIALS AND METHODS: Expressions of hTERT, p21 and p53 proteins were investigated in 188 patients with colorectal adenocarcinomas by immunohistochemistry.
  • The findings were correlated with the clinicopathological features and survival data of colorectal adenocarcinomas.
  • RESULTS: hTERT, p53 and p21 proteins were detected in 63%, 100% and 62% of the patients with colorectal carcinoma.
  • Loss or low level of p21 protein was often noted in non-mucinous colorectal adenocarcinoma when compared with mucinous adenocarcinoma (p = 0.001).
  • Furthermore, p53 expression was more frequently noted in non-mucinous adenocarcinoma (p = 0.001).
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Colorectal Neoplasms / pathology. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Telomerase / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18322660.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Tumor Suppressor Protein p53; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


12. Wisedopas N, Thirabanjasak D, Chirakalwasan N, Taweevisit M: Histological variants of colorectal adenocarcinoma and clinicomorphological association. J Med Assoc Thai; 2006 Jun;89(6):788-94
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological variants of colorectal adenocarcinoma and clinicomorphological association.
  • The objective was to provide new information of correlation between various histomorphological parameters together with available clinical data and each special feature MATERIAL AND METHOD: A retrospective study of 162 materials collected from subjects with first diagnosed as adenocarcinoma of colorectum in King Chulalongkorn Memorial Hospital over a period of 2 years from 2002 to 2003.
  • CONCLUSION: Each distinct histological variant of colorectal adenocarcinoma is associated with some different clinicopathological variables,' mostly effecting clinical outcome.
  • Pathologists should be concerned with special histological subtypes of colorectal adeonocarcinomas and communicate with physicians for proper management.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16850678.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


13. Takeda A: Use of anti-neuropilin 1, 2 antibodies to predict colorectal cancer prognosis. J Clin Oncol; 2009 May 20;27(15_suppl):e15111

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of anti-neuropilin 1, 2 antibodies to predict colorectal cancer prognosis.
  • It was reported that the expression of NRP-1 is increased by VEGF, mediated through VEGFR-2, which correlates with tumor growth and invasiveness in colorectal cancer.
  • NRP-2 knockout mice studies showed marked deficits in the development of small lymphatic vessels and its function was associated with the formation of lymphatic network, but the role of NRP-2 in colorectal cancer remains unknown.
  • In recent study, we have analyzed the expression of NRP-1 and NRP-2 in some cultured cell lines by western blot and the clinicopathological significance in colorectal cancer.
  • Tissues samples were obtained from 72 primary colorectal adenocarcinomas (colon:39 cases, rectum:33 cases).
  • NRP-1 and NRP-2 gene expression was evaluated by RT- PCR, which was compared with immunohistochemical examination of colorectal cancer tissues.
  • CONCLUSIONS: These results suggest that NRP-1 acts as angiogenesis factor and NRP-2 acts lymphangiogenesis factor, both of them are useful predictive marker in colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960860.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Glehen O, Elias D, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Association Française de Chirurgie: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from digestive or primitive origin: A multi-institutional study of 1,290 patients. J Clin Oncol; 2009 May 20;27(15_suppl):4102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The principal etiologies of PC were colorectal adenocarcinoma (N=523), pseudomyxoma peritonei (N=301), gastric adenocarcinoma (N=159), peritoneal mesothelioma (N=88), and appendiceal adenocarcinoma (N=50).
  • The overall median survival was 34 months: 30 months for colorectal PC, not reached for pseudomyxoma peritonei, 9 months for gastric PC, 41 months for peritoneal mesothelioma, and 77 months for PC from appendiceal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961196.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Feliu J, Safont M, Salud A, Losa F, García-Girón C, Bosch C, Escudero P, López R, Madroñal C, González-Barón M: Phase II study to evaluate the efficacy of capecitabine combined with bevacizumab as first-line treatment in elderly patients with advanced or metastatic colorectal adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):4119

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study to evaluate the efficacy of capecitabine combined with bevacizumab as first-line treatment in elderly patients with advanced or metastatic colorectal adenocarcinoma.
  • : 4119 Background: Colorectal adenocarcinoma is the most common cancer in subjects over 70 years old.
  • The aim of the present study is to evaluate the overall response rate in that patient's population who presents colorectal adenocarcinoma and are treated with the combination of capecitabine+BVZ.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961217.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kim J, Chae Y, Sohn S, Kang B, Lee S, Lim K, Choi G, Baek J: -93G&gt;A polymorphism of hMLH1 associated with prognosis for patients with colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4039

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] -93G>A polymorphism of hMLH1 associated with prognosis for patients with colorectal cancer.
  • : 4039 Background: Polymorphisms in the DNA repair genes may contribute to variation in DNA repair capacity, thereby affecting the risk of carcinogenesis and prognosis of colorectal cancer.
  • Accordingly, the present study analyzed polymorphisms of DNA repair genes and their impact on the prognosis for patients with colorectal cancer.
  • METHODS: Three hundred and ninety- seven consecutive patients with curatively resected colorectal adenocarcinoma were enrolled in the present study.
  • The genomic DNA was extracted from fresh colorectal tissue and 14 polymorphisms of DNA repair genes (XRCC1, hMLH1, ERCC2, ERCC4, VARS2[rs2074511, rs2249459], XPA, XPC, POLR2A, POLR2B, RFC1, RFC4, XAB2, DNMT3B) determined using a PCR-RFLP assay.
  • RESULTS: The median age of the patients was 63 years (range, 21-85), and 218 (54.9%) patients had colon cancer and 179 (45.1%) patients rectal cancer.
  • CONCLUSIONS: The -93G>A polymorphism of hMLH1 was found to be an independent prognostic marker for patients with colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961540.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Marginean EC, Torlakovic G, Neufeld H, Torlakovic E: Association of upregulated GATA-4 transcription factor colorectal adenocarcinoma with metastatic and primary tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e15093

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of upregulated GATA-4 transcription factor colorectal adenocarcinoma with metastatic and primary tumors.
  • Its protein expression in colonic adenocarcinoma has not been systematically evaluated and small number of samples was previously reported as negative.
  • Nuclear factor-B (NF-B) activation was shown to promote the growth of the colon tumors in experimental models and was correlated with tumor angiogenesis and progression in human colorectal cancer.
  • METHODS: Forty cases of colorectal adenocarcinoma were evaluated.
  • RESULTS: GATA-4 was expressed in 32% of colorectal adenocarcinoma, but not in benign colonic mucosa (p=0.0001, Chi-Square).
  • GATA-4 was also significantly more expressed in metastatic (41%) than in primary (21%) colorectal adenocarcinoma (p<0.0001, Chi-Square).
  • NF-B activation was not present in any of the samples of benign colonic mucosa, but it was detected in 64% adenocarcinomas (p<0.0001, Chi-Square).
  • While there was no difference in NF-B activation between primary vs. metastatic adenocarcinoma, a strong positive association between GATA-4 expression and NF-B activation (p<0.0001, Linear-by- Linear) was found.
  • GATA-4 may have a role in colorectal adenocarcinoma development and progression and it should be further evaluated in prospective studies as a putative adverse prognostic factor in colorectal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964606.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Posey JA, Koya S, Katkoori VR, Davis DE, Manne U: Prognostic significance of VDR, DKK-1, and DKK-4 expression in colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of VDR, DKK-1, and DKK-4 expression in colorectal cancer.
  • : e15047 Introduction: Inactivation of the vitamin D receptor (VDR) and up-regulation of its down-stream molecules, Dickkopf-1 (DKK-1) and DKK-4 are implicated in the aggressive progression of colorectal adenocarcinomas (CRC).
  • VDR expression was 2.0 fold lower in tumors that exhibited metastasis, and poor differentiation and in large tumors ( > 5) cm as compared to tumors without metastasis, well or moderately differentiated tumors and tumors of small size (< 5 cm), respectively.
  • Expression of DKK-1 was higher in tumors with poor differentiation and in large tumors.
  • These results provide evidence augmenting the VDR-DKK- pathway may represent a rational therapeutic strategy in colorectal carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964440.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Torlakovic E, Marginean EC, Torlakovic G, Geyer R, Neufeld H, Decoteau J: Downregulation of RIZ1 protein expression in left-sided versus right-sided primary colorectal carcinomas and their distant metastases and the association with NF-B activation. J Clin Oncol; 2009 May 20;27(15_suppl):e15112

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of RIZ1 protein expression in left-sided versus right-sided primary colorectal carcinomas and their distant metastases and the association with NF-B activation.
  • RIZ1 frameshift mutations were recently reported to be confined to MSI-H colorectal tumors and proximal tumor origin, while its hypermethylation was not limited to MSI-H tumors.
  • However, RIZ1 protein expression has not been evaluated in colorectal carcinoma.
  • METHODS: TMAs included 28 left-sided and 12 right-sided primary colorectal adenocarcinomas, their matched normal mucosa and their respective distant metastases.
  • CONCLUSIONS: While RIZ1 downregulation in colorectal adenocarcinoma due to RIZ1 mutations appears to be associated with MSI-H and proximal origin, its protein expression appears to be downregulated more often in distal tumors.
  • NF- B activation is strongly associated with lower RIZ1 protein expression in colorectal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960861.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Catalano V, Loupakis F, Bisonni R, Torresi U, Santini D, Silva RR, Giustini L, Falcone A, D'Emidio S, Rocchi M, Graziano F: Impact of mucinous histology on prognosis for patients with radically resected stage Dukes B2 and C colon cancer: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):4126

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of mucinous histology on prognosis for patients with radically resected stage Dukes B2 and C colon cancer: Preliminary results.
  • : 4126 Background: Previous reports have suggested that mucinous colorectal adenocarcinomas have a poorer prognosis than nonmucinous colorectal adenocarcinomas.
  • This retrospective analysis was conducted to explore whether mucinous carcinoma (MC) is associated with a worse prognosis than nonmucinous carcinoma (NMC) for patients with Dukes B2 and C radically resected colon cancer.
  • METHODS: We investigated 1,006 unselected patients who underwent curative surgery for sporadic colon cancer and followed up at six Oncology Department between 1998 and 2006.
  • RESULTS: MC accounted for 17.9% (n=180) of all colon carcinomas.
  • MC were more frequently located in the proximal colon (54.4% versus 34.6% for NMC; p<0.001).
  • Multivariate analysis using the Cox proportional hazards model showed that the clinically significant prognostic factors were stage at diagnosis (p<0.0001), grading (p<0.0001), and number of lymph node examined (p=0.0002) in the specimen.
  • CONCLUSIONS: In this preliminary analysis, patients with mucinous histology who underwent surgery with curative intent for stage Dukes B2 and C colon cancer had similar prognosis compared to NMC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961242.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Zhou YL, Deng CS: [Correlations of expressions of Glut1 and HIF-1alpha to cellular proliferation of colorectal adenocarcinoma]. Ai Zheng; 2005 Jun;24(6):685-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlations of expressions of Glut1 and HIF-1alpha to cellular proliferation of colorectal adenocarcinoma].
  • This study was to investigate the expressions of Glut1 and HIF-1alpha in colorectal adenocarcinoma, and explore their correlations to cell proliferation.
  • METHODS: Immunohistochemistry was used to detect expressions of Glut1, HIF-1alpha, and proliferating cell nuclear antigen (PCNA) in 60 specimens of colorectal adenocarcinoma and 20 specimens of normal colorectal tissues.
  • RESULTS: Positive rates of Glut1 and HIF-1alpha were significantly higher in colorectal adenocarcinoma tissues than in normal colorectal tissues (58.3% vs. 0, P < 0.01; 73.3% vs. 0, P < 0.01).
  • PCNA level was significantly higher in colorectal adenocarcinoma tissues than in normal colorectal tissues (65.25+/-16.35 vs. 15.20+/-3.47, P < 0.01).
  • CONCLUSIONS: The overexpressions of Glut1 and HIF-1alpha play important roles in carcinogenesis and progression of colorectal adenocarcinoma, and closely correlate with cell proliferation of colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Proliferation. Colorectal Neoplasms / metabolism. Glucose Transporter Type 1 / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946479.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


22. Abd El-Hameed A: Survivin expression in colorectal adenocarcinoma using tissue microarray. J Egypt Natl Canc Inst; 2005 Mar;17(1):42-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin expression in colorectal adenocarcinoma using tissue microarray.
  • This study examined the expression, and potential prognostic value of survivin in colorectal adenocarcinoma (CRC) on tissue microarray (TMA) sections.
  • Analysis of large numbers of tissue samples, improved tissue salvage, cost reduction, ease of interpretation, and significant time saving were realized by using the arrays.
  • MATERIAL AND METHODS: Two-hundred and eighty cases of colorectal adenocarcinoma were arrayed.
  • The 5-year disease free survival (DFS) for patients with survivin positive colorectal adenocarcinoma was significantly lower than that for patients with survivin negative tumors (46% versus 68.7%, p=0.001).
  • CONCLUSION: Survivin expression in colorectal adenocarcinoma provides an important prognostic parameter and targeted antagonists of survivin may be beneficial as apoptosis-based therapy for colon cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353082.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


23. Paik SS, Jang SM, Jang KS, Lee KH, Choi D, Jang SJ: Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. Ann Surg Oncol; 2009 Feb;16(2):297-303
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma.
  • We investigated leptin expression in normal and neoplastic colorectal tissues and its association with clinicopathological features and clinical outcome in colorectal adenocarcinoma patients.
  • Leptin expression was evaluated on the tissue microarray of 44 normal colon mucosal tissues, 44 adenomatous polyps, and 437 colorectal adenocarcinomas by immunohistochemistry.
  • Frequency of leptin expression was dramatically increased from normal colonic mucosa (2/44, 4.5%) to adenomas (13/44, 29.5%) and adenocarcinomas (321/437, 73.5%) as neoplastic progression.
  • In univariate survival analysis, patients with leptin-positive adenocarcinoma revealed better overall and disease-free survivals (p = 0.032 and p = 0.004, respectively, log-rank test).
  • We conclude that leptin was gradually expressed during the normal-adenoma-adenocarcinoma sequence, suggesting an association in colorectal carcinogenesis.
  • In addition, high leptin expression was an indicator of favorable tumor features and better survival of colorectal cancer patients.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Leptin / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adenomatous Polyps / metabolism. Adenomatous Polyps / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Colon / metabolism. Colon / pathology. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Phenotype. Survival Rate. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19050975.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leptin
  •  go-up   go-down


24. Park SH, Yu GR, Kim WH, Moon WS, Kim JH, Kim DG: NF-Y-dependent cyclin B2 expression in colorectal adenocarcinoma. Clin Cancer Res; 2007 Feb 1;13(3):858-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NF-Y-dependent cyclin B2 expression in colorectal adenocarcinoma.
  • PURPOSE: Cyclin B2, a G(2)-M cyclin, is overexpressed in colorectal adenocarcinomas compared with the normal mucosa.
  • This study examined the level of cyclin B2 overexpression according to the histologic findings and investigated the mechanism(s) and clinical implications of cyclin B2 overexpression in colorectal adenocarcinomas.
  • EXPERIMENTAL DESIGN: The immunoreactivity of the polyclonal antibodies to cyclin B2 was determined in colorectal cancer cells.
  • The proliferative activity of the colorectal cancer cells in relation to cyclin B2 overexpression was further examined.
  • RESULTS: The cytoplasmic distribution of cyclin B2 immunoreactivity was positive in 42 of 65 (64.6%) cases of colorectal adenocarcinoma, and the level was similar regardless of the histologic type.
  • A dominant-negative form of NF-YA effectively inhibited the cyclin B2 promoter activity, and NF-Y was found to bind three conserved CCAAT boxes in the cyclin B2 promoter in colorectal adenocarcinoma cells.
  • Furthermore, there was a correlation between the cells showing immunoreactivity to cyclin B2 and those containing the proliferating cell nuclear antigen, a G1-S cyclin, which is also downstream of NF-Y in colorectal adenocarcinoma cells.
  • CONCLUSIONS: Cyclin B2 seems to be a molecular marker of a colorectal adenocarcinoma and that its up-regulation and coordinate expression of the other cell cycle-related genes by NF-Y might contribute to tumor cell proliferation by accelerating cell cycle progression.
  • [MeSH-major] CCAAT-Binding Factor / physiology. Colorectal Neoplasms / metabolism. Cyclin B / biosynthesis. Gene Expression Regulation, Neoplastic

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17289878.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Binding Factor; 0 / CCNB2 protein, human; 0 / Cyclin B; 0 / Cyclin B2
  •  go-up   go-down


25. Ivankovics IG, Fernandes LC, Saad SS, Matos D: Peripheral and mesenteric serum levels of CEA and cytokeratins, staging and histopathological variables in colorectal adenocarcinoma. World J Gastroenterol; 2008 Nov 21;14(43):6699-703
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral and mesenteric serum levels of CEA and cytokeratins, staging and histopathological variables in colorectal adenocarcinoma.
  • AIM: To evaluate the differences that exist between peripheral and mesenteric serum levels of carcinoembryonic antigen (CEA) and cytokeratins in patients with colorectal adenocarcinoma.
  • METHODS: One hundred and thirty-eight patients with colorectal adenocarcinoma who underwent surgery at Hospital Sao Paulo (Discipline of Surgical Gastroenterology of UNIFESP-EPM) between December 1993 and March 2000 were retrospectively analyzed.
  • CONCLUSION: The mesenteric levels of the tumor markers CEA and cytokeratins were higher than the peripheral levels in these colorectal adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / pathology. Arteries. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Colorectal Neoplasms / pathology. Keratins / blood. Mesenteric Arteries

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br Med J (Clin Res Ed). 1982 Mar 13;284(6318):803-5 [6802235.001]
  • [Cites] Antibiot Chemother (1971). 1978;22:16-31 [623439.001]
  • [Cites] Cancer. 1987 Apr 1;59(7):1283-8 [3815304.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1990 May;91(5):575-80 [2385221.001]
  • [Cites] Eur J Surg Oncol. 1991 Feb;17(1):59-64 [1995360.001]
  • [Cites] Cancer. 1992 May 15;69(10):2411-7 [1568164.001]
  • [Cites] Dis Colon Rectum. 1994 Dec;37(12):1219-27 [7995147.001]
  • [Cites] Int J Biol Markers. 1994 Oct-Dec;9(4):231-8 [7836801.001]
  • [Cites] J Surg Oncol. 1996 Aug;62(4):239-44 [8691835.001]
  • [Cites] Dis Colon Rectum. 1997 Apr;40(4):483-93 [9106701.001]
  • [Cites] Arq Gastroenterol. 1997 Jan-Mar;34(1):3-6 [9458953.001]
  • [Cites] Cancer Detect Prev. 1998;22(1):57-61 [9466050.001]
  • [Cites] Recent Results Cancer Res. 1998;146:48-55 [9670248.001]
  • [Cites] J Exp Med. 1965 Mar 1;121:439-62 [14270243.001]
  • [Cites] Arq Gastroenterol. 2004 Apr-Jun;41(2):88-92 [15543380.001]
  • [Cites] World J Gastroenterol. 2005 Feb 7;11(5):645-8 [15655814.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):481-8 [15718248.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3891-4 [16804977.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):85-9 [11146784.001]
  • [Cites] Sao Paulo Med J. 2001 May 3;119(3):110-3 [11391453.001]
  • [Cites] Int J Biol Markers. 2003 Jul-Sep;18(3):182-7 [14535588.001]
  • [Cites] Br J Surg. 1982 Oct;69(10):583-4 [7127037.001]
  • (PMID = 19034974.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC2773313
  •  go-up   go-down


26. Paik SS, Jang KS, Song YS, Jang SH, Min KW, Han HX, Na W, Lee KH, Choi D, Jang SJ: Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype. Ann Surg Oncol; 2007 Dec;14(12):3453-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype.
  • We investigated the expression of Apaf-1 in colorectal tissues corresponding to the multistep carcinogenesis model to determine correlations between the clinicopathologic characteristics and the expression of this molecule and to evaluate the role of Apaf-1 in the development and progression of colorectal adenocarcinoma.
  • METHODS: Immunohistochemistry for Apaf-1 was performed on the tissue microarray of 38 normal mucosal tissues, 46 adenomatous polyps, 529 colorectal adenocarcinomas, and 76 metastatic tumors.
  • However, in colorectal adenocarcinomas, 119 of 529 cases (22.5%) were positive and 410 cases (77.5%) were negative.
  • In the analyses between Apaf-1 expression and clinicopathologic parameters, reduced expression of Apaf-1 correlated with left colon location (p < 0.001), deeper tumor invasion (p < 0.001), frequent lymph node metastasis (p = 0.021), higher American Joint Committee on Cancer (AJCC) and Dukes' stage (p = 0.02 and p = 0.001, respectively) and poorer differentiation (p < 0.001).
  • CONCLUSIONS: The results suggest that the loss of Apaf-1 expression is a relatively frequent late event and the loss of Apaf-1 expression may play an important role in tumorigenesis and tumor progression in colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptotic Protease-Activating Factor 1 / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882496.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APAF1 protein, human; 0 / Apoptotic Protease-Activating Factor 1; 0 / Biomarkers, Tumor
  •  go-up   go-down


27. Choi D, Lee HW, Hur KY, Kim JJ, Park GS, Jang SH, Song YS, Jang KS, Paik SS: Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol; 2009 May 14;15(18):2258-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma.
  • AIM: To verify that CD markers are available for detecting cancer stem cell populations and to evaluate their clinical significance in colon cancer.
  • METHODS: Immunohistochemistry for CD133, CD24 and CD44 was performed on the tissue microarray of 523 colorectal adenocarcinomas.
  • RESULTS: In colorectal adenocarcinoma, 128 of 523 cases (24.5%) were positive and 395 cases (75.5%) were negative for CD133 expression.
  • CONCLUSION: CD markers were related to invasiveness and differentiation of colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Antigens, CD / metabolism. Antigens, CD24 / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms. Glycoproteins / metabolism. Neoplasm Invasiveness. Neoplastic Stem Cells / metabolism. Peptides / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Cancer J. 2007 May-Jun;13(3):192-7 [17620769.001]
  • [Cites] J Immunol. 1986 May 15;136(10):3779-84 [2939133.001]
  • [Cites] J Immunol. 1990 Jan 15;144(2):638-41 [2153173.001]
  • [Cites] J Immunol. 1991 Aug 15;147(4):1412-6 [1831224.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5264-70 [1327504.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):4754-6 [7691404.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Virchows Arch. 1994;425(4):399-406 [7820302.001]
  • [Cites] Am J Pathol. 1996 Nov;149(5):1519-30 [8909242.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):495-502 [15513931.001]
  • [Cites] Cell. 2005 May 6;121(3):465-77 [15882627.001]
  • [Cites] Pathol Res Pract. 2005;201(7):479-86 [16164042.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6574-81 [16166435.001]
  • [Cites] Cell. 2006 Aug 25;126(4):663-76 [16904174.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1253-61 [16990388.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3153-61 [17409422.001]
  • [Cites] Mod Pathol. 2003 Apr;16(4):376-88 [12692203.001]
  • (PMID = 19437567.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD24; 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides
  • [Other-IDs] NLM/ PMC2682242
  •  go-up   go-down


28. Zhang MQ, Chen ZM, Wang HL: Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma: a comparison with colorectal adenocarcinoma. Mod Pathol; 2006 Apr;19(4):573-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma: a comparison with colorectal adenocarcinoma.
  • Small intestinal adenocarcinoma is an uncommon neoplasm morphologically similar to or indistinguishable from colorectal adenocarcinoma.
  • Although much has been learned about genetic pathways critical to colorectal tumorigenesis, little is known about molecular alterations involved in the development of small intestinal adenocarcinoma.
  • In this study, we immunohistochemically compared non-ampullary small intestinal adenocarcinomas with sporadic colorectal adenocarcinomas for the expression of several proteins known to serve pivotal roles in colorectal tumorigenesis.
  • The results show that complete loss of adenomatous polyposis coli immunoreactivity, presumably resulting from its gene mutations, was observed in eight of 26 (31%) small intestinal adenocarcinomas and 36 of 51 (71%) colorectal adenocarcinomas (P = 0.0008).
  • Nuclear localization of beta-catenin, an indirect evidence of deregulated Wnt signaling pathway, was observed in 5 (19%) small intestinal adenocarcinomas and 36 (71%) colorectal adenocarcinomas (P<0.0001).
  • Total lack of nuclear staining for one or more of the DNA mismatch repair enzymes occurred in a similar low frequency in both small intestinal and colorectal adenocarcinomas, seen in two of 25 (8%) and 10 of 47 (21%) cases, respectively (P = 0.1958).
  • The frequencies of aberrant p53 and RB expression were also similar between small intestinal and colorectal adenocarcinomas.
  • These observations indicate that defects in the Wnt and microsatellite instability pathways occur in over 90% of colorectal adenocarcinomas, but in only 40% of small intestinal adenocarcinomas.
  • Small intestinal tumorigenesis appears to follow a distinct, yet unidentified, molecular pathway(s) from its colorectal counterpart despite their morphologic similarity.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Intestinal Neoplasms / pathology. Intestine, Small / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501564.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Adenomatous Polyposis Coli Protein; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / MLH2 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Retinoblastoma Protein; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin
  •  go-up   go-down


29. Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, Zhu RM, Li GL, Xia XY, Wei XW, Ji HZ, Lu H, Gao Y, Gao WM, Chen LB: Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol; 2008 May 21;14(19):3074-80
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients.
  • AIM: To evaluate the diagnostic role of serum RASSF1A promoter hypermethylation in gastric and colorectal adenocarcinoma.
  • METHODS: Methylation-specific polymerase chain reaction (MSPCR) was used to examine the promoter methylation status of the serum RASSF1A gene in 47 gastric adenocarcinoma patients, 45 colorectal adenocarcinoma patients, 60 patients with benign gastrointestinal disease (30 with benign gastric disease and 30 with benign colorectal disease), and 30 healthy donor controls.
  • A paired study of RASSF1A promoter methylation status in primary tumor, adjacent normal tissue, and postoperative serum were conducted in 25 gastric and colorectal adenocarcinoma patients who later were underwent surgical therapy.
  • RESULTS: The frequencies of detection of serum RASSF1A promoter hypermethylation in gastric (34.0%) and colorectal (28.9%) adenocarcinoma patients were significantly higher than those in patients with benign gastric (3.3%) or colorectal (6.7%) disease or in healthy donors (0%) (P < 0.01).
  • CONCLUSION: Aberrant CpG island methylation within the promoter region of RASSF1A is a promising biomarker for gastric and colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. DNA Methylation. DNA, Neoplasm / blood. Promoter Regions, Genetic. Stomach Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2000 Dec;30(3):211-4 [11147802.001]
  • [Cites] Oncol Rep. 2007 Nov;18(5):1225-30 [17914577.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7034-8 [11585730.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(12):4309-18 [12024041.001]
  • [Cites] Oncogene. 2002 May 23;21(23):3792-5 [12032847.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1761-6 [12060614.001]
  • [Cites] Oncogene. 2002 Oct 17;21(47):7277-82 [12370819.001]
  • [Cites] Int J Cancer. 2002 Dec 20;102(6):623-8 [12448005.001]
  • [Cites] J Pathol. 2003 May;200(1):23-31 [12692837.001]
  • [Cites] Cancer Lett. 2003 Apr 25;193(2):207-16 [12706879.001]
  • [Cites] Cancer Lett. 2003 May 8;194(1):99-105 [12706863.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8125-36 [14603253.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):96-100 [15185349.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4244-50 [15205337.001]
  • [Cites] Cancer Res. 1977 Mar;37(3):646-50 [837366.001]
  • [Cites] Oncology. 1989;46(5):318-22 [2779946.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5):556-60 [10528904.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3441-54 [15526363.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1219-25 [15709192.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1141-5 [15734995.001]
  • [Cites] Histol Histopathol. 2005 Apr;20(2):645-63 [15736067.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3682-90 [15867363.001]
  • [Cites] Biochemistry (Mosc). 2005 May;70(5):576-83 [15948711.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1293-6 [16001680.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5205-10 [16051962.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7653-9 [16140931.001]
  • [Cites] Oncogene. 2005 Nov 17;24(51):7630-4 [16007118.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):339-46 [16139926.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):315-9 [10888881.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):35669-72 [10998413.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):192-8 [16482617.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):4557-63 [16344548.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Lung Cancer. 2007 May;56(2):289-94 [17267069.001]
  • [Cites] BMC Cancer. 2007;7:120 [17608924.001]
  • [Cites] Int J Surg Pathol. 2007 Jul;15(3):242-51 [17652530.001]
  • [Cites] J Cell Sci. 2007 Sep 15;120(Pt 18):3163-72 [17878233.001]
  • [Cites] Mol Cell. 2007 Sep 21;27(6):962-75 [17889669.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):691-9 [11333291.001]
  • (PMID = 18494062.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2712178
  •  go-up   go-down


30. Díez M, Pollán M, Ramos P, Villeta R, Ratia T, Hernández P, Lozano O, Noguerales F, Granell J: [Variation in the prognostic value of p53 protein in relation to tumoral stage in patients with colorectal adenocarcinoma]. Cir Esp; 2005 Apr;77(4):213-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Variation in the prognostic value of p53 protein in relation to tumoral stage in patients with colorectal adenocarcinoma].
  • [Transliterated title] Variación del valor pronóstico de la proteína p53 en relación con el estadio tumoral en pacientes con adenocarcinoma colorrectal.
  • PATIENTS AND METHOD: A prospective study of a cohort of 288 patients who underwent surgery for colorectal adenocarcinoma was performed.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / surgery. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / surgery. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420920.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


31. Wu CY, Lee WH, Wang JY, Chiang H, Chang JL, Tsai WC, Sheu LF, Jin JS: Tissue microarray-determined expression profiles of cyclooxygenase-2 in colorectal adenocarcinoma: association with clinicopathological parameters. Chin J Physiol; 2006 Dec 31;49(6):298-304
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue microarray-determined expression profiles of cyclooxygenase-2 in colorectal adenocarcinoma: association with clinicopathological parameters.
  • Accumulated evidence reveals that increased cyclooxygenase-2 (COX-2) is involved in the development of colorectal cancer.
  • Our purpose was to quantitate COX-2 expression in colorectal cancers using tissue microarray analysis and look for an association with clinicopathological stage.
  • Immunohistochemical analysis of COX-2 was performed in tissue microarray slides containing 90 specimens including 32 well-differentiated, 35 moderately differentiated, and 23 poorly differentiated colorectal adenocarcinomas.
  • All colorectal adenocarcinomas showed significant immunohistochemical expression of COX-2 when compared to normal colon epithelia.
  • The positive expression rates of CK20 were 97% for well-differentiated, 94% for moderately differentiated, and 65% for poorly differentiated colorectal adenocarcinomas, suggesting that CK20 may not be an effective discriminator between poorly differentiated colorectal adenocarcinoma and metastatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / enzymology. Colorectal Neoplasms / enzymology. Cyclooxygenase 2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357536.001).
  • [ISSN] 0304-4920
  • [Journal-full-title] The Chinese journal of physiology
  • [ISO-abbreviation] Chin J Physiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


32. Lam AK, Ong K, Ho YH: Aurora kinase expression in colorectal adenocarcinoma: correlations with clinicopathological features, p16 expression, and telomerase activity. Hum Pathol; 2008 Apr;39(4):599-604
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aurora kinase expression in colorectal adenocarcinoma: correlations with clinicopathological features, p16 expression, and telomerase activity.
  • The clinicopathological roles of aurora kinase protein have not been studied in depth in colorectal cancer.
  • The aim of the present study was to investigate the clinicopathological roles of aurora kinase protein expression in a large cohort of patients with colorectal adenocarcinoma with tight methodology and close follow-up.
  • Aurora kinase protein expression was investigated in 200 patients (110 men, 90 women) with colorectal adenocarcinomas by immunohistochemistry.
  • The findings were correlated with the clinicopathological features, p16 expression, and telomerase activity of colorectal adenocarcinomas.
  • Aurora kinase protein was detected in 48.5% (97/200) of patients with colorectal carcinoma.
  • The protein was more frequently detected in patients with well or moderately differentiated colorectal carcinomas than in poorly differentiated colorectal adenocarcinomas (52% versus 31%, P = .004).
  • Mucinous adenocarcinomas were less often positive for the protein (16% versus 56%, P = .0001).
  • Aurora kinase protein expression was more commonly seen in carcinomas in the rectum, sigmoid, and descending colon than in the proximal colon (55% versus 36%, P = .01).
  • Also, aurora kinase protein expression was related to the expression of p16 protein (P = .001) and correlated inversely with the level of telomerase activity in colorectal carcinomas (P = .005).
  • To conclude, aurora kinase protein is expressed in a subset of colorectal carcinoma.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / pathology. Protein-Serine-Threonine Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284933.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


33. Arfa N, Hamdani I, Gharbi L, Ben Abid S, Ghariani B, Mannai S, Mestiri H, Khalfallah MT, Mzabi SR: [Survival and prognostic factors of colorectal adenocarcinoma: analytic multifactor review of 150 cases]. Ann Chir; 2006 Feb;131(2):104-11
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival and prognostic factors of colorectal adenocarcinoma: analytic multifactor review of 150 cases].
  • [Transliterated title] Survie et facteurs pronostiques des adénocarcinomes colorectaux: étude analytique uni- et multifactorielle de 150 cas.
  • The number of possibility useful prognosis factors in the colorectal cancer is large.
  • This study attempts to observe the survival of colorectal adenocarcinoma and to find prognostic factors and other variables potentially associated with outcome of colorectal adenocarcinoma.
  • MATERIAL AND METHODS: It's a retrospective study based on 150 patients with colorectal adenocarcinoma from 1990 to 2002.
  • 84 patients had colon adenocarcinoma and 66 patients had rectal adenocarcinoma.
  • In histological exam the adenocarcinoma was well differenced in 69 cases (46%), and undifferentiated in 17 cases (18, 3%).
  • All patients had surgical curative resection associated with adjuvant chemotherapy in 60 cases of colon adenocarcinoma and preoperative radiotherapy in 33 cases of rectal adenocarcinoma.
  • In addition to the clinical factors, we found of significant prognostic value undifferentiated adenocarcinoma and an elevated value of serum carcinoembryonic antigen>5 ng/ml.
  • [MeSH-major] Adenocarcinoma / mortality. Colorectal Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16443189.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


34. Gómez Del Pulgar T, Valdés-Mora F, Bandrés E, Pérez-Palacios R, Espina C, Cejas P, García-Cabezas MA, Nistal M, Casado E, González-Barón M, García-Foncillas J, Lacal JC: Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism. Int J Oncol; 2008 Jul;33(1):185-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism.
  • Here, the specific role of Cdc42 in development and progression of colorectal cancer was analyzed through microarrays technology.
  • Colorectal adenocarcinoma samples were compared with the corresponding adjacent normal tissue of the same patient in order to determine specific gene expression levels.
  • The downregulation of ID4 by Cdc42 was also found of relevance in colorectal adenocarcinoma biopsies.
  • Cdc42 was found to be overexpressed with high incidence (60%) in colorectal cancer samples, and this expression was associated with silencing of ID4 with statistical significance (p<0.05).
  • Cdc42 may have a role in the development of colon cancer.
  • Furthermore, inhibition of Cdc42 activity may have a direct impact in the management of colorectal cancer.
  • [MeSH-major] Adenocarcinoma / chemistry. Colorectal Neoplasms / chemistry. Inhibitor of Differentiation Proteins / genetics. cdc42 GTP-Binding Protein / physiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575765.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ID4 protein, human; 0 / Inhibitor of Differentiation Proteins; EC 3.6.5.2 / cdc42 GTP-Binding Protein
  •  go-up   go-down


35. Zhang J, Ding Y, Zhou Z, Li H, Zhou B: [Expression of human papillomavirus 16 E7 DNA in patients with colorectal adenocarcinoma]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2005 Oct;22(5):1024-6, 1044
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of human papillomavirus 16 E7 DNA in patients with colorectal adenocarcinoma].
  • The relationship between Human papillomavirus (HPV) 16 infection and the natural course of colorectal adenocarcinoma has not been fully defined.
  • In this study, the HPV 16 E7 DNA was detected in 82 patients with primary colorectal adenocarcinoma to study the relationship between HPV 16 infection and colorectal carcinoma.
  • Our results showed HPV16 E7 DNA expression was significantly higher in colorectal carcinoma (42/82) than in adjacent normal mucosa (4/82).
  • The correlation was found between HPV16 E7 expression and tumor's location; the positive rate was 18.18% in the ascending colon carcinoma group and 64.10% in the rectal carcinoma group.
  • These results indicated that there was correlation between colorectal adenocarcinoma and HPV 16 infection.
  • HPV16 infection was relatively higher in the colorectal carcinoma and rare in the adjacent normal mucosa.
  • [MeSH-major] Adenocarcinoma / virology. Colorectal Neoplasms / virology. Oncogene Proteins, Viral / biosynthesis. Papillomavirus Infections / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16294745.001).
  • [ISSN] 1001-5515
  • [Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi
  • [ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / oncogene protein E7, Human papillomavirus type 16
  •  go-up   go-down


36. Seo JO, Han SI, Lim SC: Role of CDK8 and beta-catenin in colorectal adenocarcinoma. Oncol Rep; 2010 Jul;24(1):285-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of CDK8 and beta-catenin in colorectal adenocarcinoma.
  • Colorectal adenocarcinoma is a major cause of morbidity and mortality.
  • The Wnt/beta-catenin pathway plays an important role in colon cancers.
  • However, relatively little is known about the regulatory mechanism of beta-catenin in colon cancers.
  • CDK8 is a cyclin-dependent kinase (CDK) member of the mediator complex that couples transcriptional regulators to the basal transcriptional machinery, and is implicated in the transcriptional regulation of key pathways involved in colon cancers.
  • To determine the relationship between CDK8 and beta-catenin expressions, a population-based study was conducted for immunohistochemical staining analysis of tumor tissues, and Western blot analysis and CDK8 interference studies of colon cancer cell lines.
  • The hypothesis that colorectal cancers with CDK8 expression have distinct clinical, prognostic and molecular attributes was tested.
  • Among 127 colorectal cancers, CDK8 expression was detected in 96 (76%) tumors by immunohistochemistry.
  • Immunohistochemically, CDK8 expression in colorectal cancer was independently associated with beta-catenin activation (P=0.0002).
  • However, beta-catenin expression was not completely suppressed by CDK8 interference in the colon cancer cell lines HCT-116, HT-29 and SNU-C5.
  • These data support a potential link between CDK8 and beta-catenin, and suggest that CDK8 may identify a subset of colon cancer patients with a poor prognosis.
  • However, control of CDK8 is not an effective therapeutic strategy through beta-catenin regulation of general colon cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Cyclin-Dependent Kinase 8 / physiology. beta Catenin / physiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514474.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / beta Catenin; EC 2.7.11.22 / CDK8 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 8
  •  go-up   go-down


37. Haupt B, Ro JY, Schwartz MR, Shen SS: Colorectal adenocarcinoma with micropapillary pattern and its association with lymph node metastasis. Mod Pathol; 2007 Jul;20(7):729-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal adenocarcinoma with micropapillary pattern and its association with lymph node metastasis.
  • This study explored the clinicopathological features of colorectal adenocarcinoma with a micropapillary carcinoma component and compared them with those of conventional colorectal adenocarcinoma.
  • One hundred seventy-eight consecutive cases of surgically resected colorectal carcinomas were studied for tumor size, type, depth of invasion, nodal and distant metastases, tumor stage, and percentage and extent of micropapillary component.
  • Among 178 cases of colorectal carcinoma, 34 (19.1%) cases had a micropapillary component, which ranged from 5 to 60% of the entire tumor.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Papillary / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17464318.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Nunes BL, Jucá MJ, Gomes EG, Menezes HL, Costa HO, Matos D, Saad SS: Metalloproteinase-1, metalloproteinase-7, and p53 immunoexpression and their correlation with clinicopathological prognostic factors in colorectal adenocarcinoma. Int J Biol Markers; 2009 Jul-Sep;24(3):156-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metalloproteinase-1, metalloproteinase-7, and p53 immunoexpression and their correlation with clinicopathological prognostic factors in colorectal adenocarcinoma.
  • AIM: The aim of this study was to analyze the immunoexpression of metalloproteinase-1, metalloproteinase-7, and p53 in colorectal adenocarcinoma, and to correlate this with clinicopathological prognostic factors.
  • CONCLUSION: The immunoexpression of metalloproteinase-1, metalloproteinase-7, and p53 did not correlate with recurrence, mortality, relapse-free survival, survival, degree of cell differentiation, or staging of colorectal cancer.
  • [MeSH-major] Colonic Neoplasms / pathology. Colorectal Neoplasms / pathology. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 7 / metabolism. Rectal Neoplasms / pathology. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787626.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


39. Hong R, Lim SC: Pathological significance of connexin 26 expression in colorectal adenocarcinoma. Oncol Rep; 2008 Apr;19(4):913-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological significance of connexin 26 expression in colorectal adenocarcinoma.
  • This study was conducted to determine the level of expression and cellular localization of connexin 26 (Cx26) and the expression of p53 in colorectal adenocarcinoma as well as their relationship to clinicopathological features.
  • Immunohistochemical staining was performed in 130 colorectal adenocarcinoma cases.
  • There was a statistical significant difference in the Cx26 expression level among normal epithelium (NE), adenomas and adenocarcinomas (p<0.001).
  • Of the 130 adenocarcinomas, 48.5% were positive for Cx26.
  • Cytoplasmic staining for Cx26 was observed in the adenocarcinomas (23.8%), but was not observed in the adenoma and NE samples.
  • Expression of p53 was positive for 50% of the adenocarcinomas, and the level of p53 was increased in a reverse proportion to the level of Cx26 intercellular staining.
  • In conclusion, loss of intercellular and gain of intracytoplasmic Cx26 expression may play a role in colorectal carcinogenesis and tumor progression.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Connexins / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357375.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Connexins; 127120-53-0 / connexin 26
  •  go-up   go-down


40. Cressey R, Pimpa S, Tontrong W, Watananupong O, Leartprasertsuke N: Expression of cyclooxygenase-2 in colorectal adenocarcinoma is associated with p53 accumulation and hdm2 overexpression. Cancer Lett; 2006 Feb 28;233(2):232-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cyclooxygenase-2 in colorectal adenocarcinoma is associated with p53 accumulation and hdm2 overexpression.
  • The aim of this study was to examine the correlation between COX-2 overexpression, p53 accumulation and HDM2 overexpression, as indications of p53 anomalies, and their relationship to clinicopathologic features of colorectal adenocarcinoma.
  • Tumor tissues and the adjacent normal mucosa were obtained from 73 colorectal cancer patients who underwent curative resection at Maharaj Nakorn Chiang Mai Hospital.
  • No normal colorectal tissues possessed detectable levels of COX-2, p53 or HDM2.
  • The results obtained from this study indicate that overexpression of COX-2 is frequently associated with p53 protein accumulation and HDM2 overexpression, therefore the COX-2 overexpression observed in colorectal cancer cells may be partly due to the dysfunction of p53.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Cyclooxygenase 2 / metabolism. Gene Expression Regulation, Neoplastic. Proto-Oncogene Proteins c-mdm2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921850.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 1.14.99.1 / Cyclooxygenase 2; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


41. Rekhi B, George S, Madur B, Chinoy RF, Dikshit R, Maheshwari A: Clinicopathological features and the value of differential Cytokeratin 7 and 20 expression in resolving diagnostic dilemmas of ovarian involvement by colorectal adenocarcinoma and vice-versa. Diagn Pathol; 2008;3:39
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features and the value of differential Cytokeratin 7 and 20 expression in resolving diagnostic dilemmas of ovarian involvement by colorectal adenocarcinoma and vice-versa.
  • The distinction between metastasis from a colorectal adenocarcinoma into the ovary and an ovarian adenocarcinoma is vital, but challenging at times, due to overlapping morphological features.
  • Similarly, a distinction between an ovarian metastasis into the colorectum and a colorectal adenocarcinoma, although rare; is important and can be daunting.
  • We report an analysis of 20 cases of ovarian involvement by metastatic colorectal adenocarcinomas and colorectal involvement by metastatic ovarian adenocarcinomas, including the value of differential expression of cytokeratins 7 & 20 by immunohistochemistry (IHC), in these cases.
  • Nine cases (45%) were identified as colorectal adenocarcinomas metastatic to the ovary.
  • Other 11 cases (55%) were ovarian adenocarcinomas, metastatic to the colorectum.
  • These showed metachronous presentations, with the ovarian tumor preceding the colorectal tumor deposits.
  • On IHC, CK7 and CA 125 were positive in all 6 of 11 such cases, whereas CK 20 was negative in all these cases.In cases of complex presentations like an ovarian involvement by a metastatic colorectal adenocarcinoma and vice-versa, certain clinicopathological features are useful.
  • CK20 positivity and CK7 negativity is associated with a colorectal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1130-9 [16931958.001]
  • [Cites] Am J Clin Pathol. 2002 Jun;117(6):944-51 [12047147.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):97-101 [16278010.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):177-84 [16434891.001]
  • [Cites] Histopathology. 2005 Sep;47(3):231-47 [16115224.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1312-4; discussion 1314-5 [9788396.001]
  • [Cites] Hum Pathol. 1998 May;29(5):491-7 [9596273.001]
  • [Cites] Jpn J Clin Oncol. 1997 Jun;27(3):193-6 [9255277.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):368-81 [8996164.001]
  • [Cites] Gynecol Oncol. 1995 Nov;59(2):200-6 [7590473.001]
  • [Cites] Am J Pathol. 1992 Feb;140(2):427-47 [1371204.001]
  • [Cites] Am J Clin Pathol. 1992 Jun;97(6):745-7 [1595593.001]
  • [Cites] Cancer. 1989 Oct 1;64(7):1508-13 [2776109.001]
  • [Cites] Am J Surg Pathol. 1987 Feb;11(2):114-21 [3812871.001]
  • [Cites] Am J Pathol. 1990 Mar;136(3):641-55 [1690512.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):850-3 [15350388.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1078-85 [12454811.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):3-32 [16512597.001]
  • (PMID = 18801162.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2556647
  •  go-up   go-down


42. Tomaszewski JJ, Smaldone MC, Benoit RM: Inguinal canal recurrence of colorectal adenocarcinoma following cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Can J Urol; 2008 Dec;15(6):4428-30
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inguinal canal recurrence of colorectal adenocarcinoma following cytoreductive surgery and intraperitoneal hyperthermic chemotherapy.
  • Peritoneal carcinomatosis, the second most common cause of death among patients with colorectal carcinoma, may be managed with cytoreductive surgery and adjuvant intraoperative peritoneal hyperthermic chemotherapy (IHPC).
  • We present the case of a 35-year-old male with locally recurrent colorectal adenocarcinoma in the inguinal canal and testis following intraperitoneal debulking and IPHC.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Adenocarcinoma / therapy. Colorectal Neoplasms / therapy. Hyperthermia, Induced. Inguinal Canal / radionuclide imaging. Neoplasms, Second Primary / radionuclide imaging. Testicular Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046498.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


43. Tsai WC, Sheu LF, Chao YC, Chen A, Chiang H, Jin JS: Decreased matriptase/HAI-1 ratio in advanced colorectal adenocarcinoma of Chinese patients. Chin J Physiol; 2007 Oct 31;50(5):225-31
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased matriptase/HAI-1 ratio in advanced colorectal adenocarcinoma of Chinese patients.
  • We tested the expressions of matriptase and hepatocyte growth factor activator inhibitor-1 (HAI-1) maybe associated with the progression of colorectal adenocarcinoma.
  • Immunohistochemical analysis of matriptase and HAI-1 was performed in tissue microarray slides of 91 colorectal adenocarcinomas with various degrees.
  • The matriptase scores in moderately (346.7 +/- 10.6) and poorly differentiated (248.1 +/- 12.9) were significantly lower than those in well differentiated (368.4 +/- 9.6) colorectal adenocarcinomas.
  • The matriptase/HAI-1 ratios in poorly (1.8 +/- 0.4) and moderately differentiated (1.8 +/- 0.3) were significantly lower than in well differentiated (2.2 +/- 0.2) colorectal adenocarcinomas.
  • Otherwise, the matriptase scores and matriptase/HAI-1 ratio showed significant reverse correlation with more advanced TNM stages of colorectal adenocarcinomas in Chinese patients.
  • In conclusion, pharmacological inhibitors of matriptase may not be effective treatment for advanced colorectal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Asian Continental Ancestry Group. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / pathology. Proteinase Inhibitory Proteins, Secretory / metabolism. Serine Endopeptidases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18274158.001).
  • [ISSN] 0304-4920
  • [Journal-full-title] The Chinese journal of physiology
  • [ISO-abbreviation] Chin J Physiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Proteinase Inhibitory Proteins, Secretory; 0 / SPINT1 protein, human; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / matriptase
  •  go-up   go-down


44. Liu CY, Liao HF, Wang TE, Lin SC, Shih SC, Chang WH, Yang YC, Lin CC, Chen YJ: Etoposide sensitizes CT26 colorectal adenocarcinoma to radiation therapy in BALB/c mice. World J Gastroenterol; 2005 Aug 21;11(31):4895-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etoposide sensitizes CT26 colorectal adenocarcinoma to radiation therapy in BALB/c mice.
  • AIM: To investigate the combined effect of etoposide and radiation on CT26 colorectal adenocarcinoma implanted into BALB/c mice.
  • METHODS: We evaluated the radiosensitizing effect of etoposide on CT26 colorectal adenocarcinoma in a syngeneic animal model.
  • CONCLUSION: Etoposide can sensitize CT26 colorectal adenocarcinoma in BALB/c mice to RT without significant toxicity.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Colorectal Neoplasms / radiotherapy. Etoposide / therapeutic use. Radiotherapy / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16097067.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide
  • [Other-IDs] NLM/ PMC4398745
  •  go-up   go-down


45. Gomes EG, Jucá MJ, de Menezes HL, Nunes BL, Costa H, Lima Fde O, Matos D: Correlation between the immunohistochemical expressions of MMP-1, MMP-7 and VEGF and prognostic factors in colorectal adenocarcinoma. Acta Cir Bras; 2009 Jul-Aug;24(4):303-10
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between the immunohistochemical expressions of MMP-1, MMP-7 and VEGF and prognostic factors in colorectal adenocarcinoma.
  • PURPOSE: To analyze the expression of metalloproteinase-1, metalloproteinase-7 and vascular endothelial growth factor (VEGF) in colorectal adenocarcinoma, and to correlate these with the clinical-pathological prognostic factors.
  • CONCLUSION: The associated expression of metalloproteinase-1, metalloproteinase-7 and VEGF in colorectal adenocarcinoma is related to the incidence of disease recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19705030.001).
  • [ISSN] 1678-2674
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


46. Menezes HL, Jucá MJ, Gomes EG, Nunes BL, Costa HO, Matos D: Analysis of the immunohistochemical expressions of p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and their correlations with the prognostic factors. Arq Gastroenterol; 2010 Apr-Jun;47(2):141-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the immunohistochemical expressions of p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and their correlations with the prognostic factors.
  • CONTEXT: Search of tumors markers that allow treatment with higher survival rates, and indicate the response to treatment and recurrence of cancer OBJECTIVE: To analyze the immunoexpression of the proteins p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and correlate them with the clinical-pathological prognostic factors.
  • METHOD: Tissue microarray paraffin blocks were made from colorectal adenocarcinoma tissue resected from 82 patients who had undergone surgery but not chemotherapy or radiotherapy, at "Hospital São Paulo", São Paulo, SP, Brazil, between 2002 and 2005.
  • CONCLUSION: The immunohistochemical expression of Ki-67 in colorectal cancer is associated with recurrence of this disease.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Ki-67 Antigen / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20721457.001).
  • [ISSN] 1678-4219
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


47. Ren DN, Kim IY, Koh SB, Chang SJ, Eom M, Yi SY, Seong SH, Kim MD, Bronner MP, Cho MY: Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma. J Surg Oncol; 2009 Dec 1;100(7):546-52
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma.
  • BACKGROUND AND OBJECTIVES: To determine the best routinely available molecular methodology for assessing thymidylate synthase (TS) as a prognostic marker in colorectal adenocarcinoma, TS was examined at the protein, mRNA, and DNA levels.
  • Direct comparison of these routinely available assays has not been systematically studied across a large colon cancer patient cohort with long-term follow-up.
  • METHODS: We studied 150 surgically resected colorectal adenocarcinoma patients who received postoperative 5-Fluorouracil (5-FU) chemotherapy.
  • CONCLUSION: TS genotyping on paraffin-embedded fixed tissues proved to be the most useful method for prediction of outcome of 5-FU treatment in patients with colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / mortality. Colorectal Neoplasms / mortality. DNA / metabolism. RNA, Messenger / metabolism. Thymidylate Synthase / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19722231.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 9007-49-2 / DNA; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  •  go-up   go-down


48. Huh JW, Lee JH, Kim HR: Expression of p16, p53, and Ki-67 in colorectal adenocarcinoma: a study of 356 surgically resected cases. Hepatogastroenterology; 2010 Jul-Aug;57(101):734-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p16, p53, and Ki-67 in colorectal adenocarcinoma: a study of 356 surgically resected cases.
  • BACKGROUND/AIMS: The aim of the present study was to investigate the clinicopathological significance of p53, Ki-67, and p16 expression in patients with colorectal adenocarcinoma.
  • METHODOLOGY: We evaluated p53, Ki-67, and p16 expression in 356 patients with primary colorectal adenocarcinoma using an immunohistochemical staining method.
  • RESULTS: Positive p53 staining was detected more often in typical adenocarcinoma compared to mucinous adenocarcinoma (49% versus 17%, p = 0.007) and in well or moderately differentiated adenocarcinoma compared to poorly differentiated adenocarcinoma (50% versus 32%, p = 0.030).
  • The level of expression of p53 protein was related to lymph node metastasis (p < 0.001) and the TNM stage of the colorectal adenocarcinoma (p = 0.006).
  • CONCLUSIONS: Our data suggest that overexpression of p53, which was correlated with Ki-67 and p16 expression, plays a critical role in aggressive tumor behaviors in patients with colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Ki-67 Antigen / metabolism. Neoplasm Proteins / metabolism. Rectal Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21033219.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


49. Yin A, Jiang Y, Zhang X, Luo H: Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells. Med Oncol; 2010 Jun;27(2):397-405
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells.
  • To investigate the mechanism of enhancing apoptosis-inducing effects of 5-fluorouracil on human colorectal adenocarcinoma cells by stable transfection of extrinsic Fas-associated death domain protein (FADD) gene, both in vitro and in vivo.
  • Stable overexpression of extrinsic FADD gene can conspicuously ameliorate apoptosis-inducing effects of 5-fluorouracil on colorectal adenocarcinoma cells, which is a novel strategy to improve chemotherapeutic effects on colorectal cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis / drug effects. Colorectal Neoplasms / metabolism. Fas-Associated Death Domain Protein / biosynthesis. Fluorouracil / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Up-Regulation / drug effects

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415536.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fas-Associated Death Domain Protein; U3P01618RT / Fluorouracil
  •  go-up   go-down


50. Lustosa SA, Logullo A, Artigiani R, Saad SS, Goldenberg A, Matos D: Analysis of the correlation between p53 and bcl-2 expression with staging and prognosis of the colorectal adenocarcinoma. Acta Cir Bras; 2005 Sep-Oct;20(5):353-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the correlation between p53 and bcl-2 expression with staging and prognosis of the colorectal adenocarcinoma.
  • PURPOSE: To analyze the correlation between p53 and bcl-2 expression and colorectal adenocarcinoma staging and prognosis.
  • METHODS: This was a retrospective series of 125 colorectal adenocarcinoma patients (67 women and 58 men; ages 30-87 years) who underwent surgery with curative intent.
  • CONCLUSION: No correlation was found between tumor expression of p53 and bcl-2 and the TNM staging, recurrence, survival and cancer-related mortality in colorectal adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16186958.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


51. Fernandes LC, Kim SB, Matos D: Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma. World J Gastroenterol; 2005 Feb 7;11(5):645-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma.
  • AIM: To evaluate the serum levels of cytokeratins and carcinoembryonic antigen (CEA) in diagnosis, staging and prognosis of patients with colorectal adenocarcinoma.
  • RESULTS: In the diagnosis of patients with colorectal adenocarcinoma, CEA showed a sensitivity of 56%, a specificity of 95%, a positive predictive value of 94%, a negative predictive value of 50% and an accuracy of 76.8%.
  • CONCLUSION: Cytokeratins demonstrate a greater sensitivity than CEA in the diagnosis of colorectal adenocarcinoma.
  • Cytokeratins constitute an advance in the direction of a perfect tumor marker in the treatment of patients with colorectal cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoembryonic Antigen / blood. Colorectal Neoplasms / pathology. Keratins / blood. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655814.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC4250731
  •  go-up   go-down


52. Chen L, Zhu YY, Zhang XJ, Wang GL, Li XY, He S, Zhang JB, Zhu JW: TSPAN1 protein expression: a significant prognostic indicator for patients with colorectal adenocarcinoma. World J Gastroenterol; 2009 May 14;15(18):2270-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TSPAN1 protein expression: a significant prognostic indicator for patients with colorectal adenocarcinoma.
  • AIM: To determine if TSPAN1 overexpression is associated with clinicopathological and prognostic factors in human colorectal adenocarcinoma.
  • METHODS: Total RNA was extracted in 20 human adenocarcinoma tissues for TSPAN1 mRNA assay by RT-PCR.
  • Eighty-eight specimens of human colorectal adenocarcinoma were surgically removed.
  • The light density of TSPAN1 mRNA expression levels was 0.89 +/- 0.30 in adenocarcinoma by gel-image system.
  • TSPAN1 protein expression was detected in 78.41% (69/88) and weakly expressed in 40% normal colorectal tissues.
  • There were significant differences between colorectal adenocarcinoma and normal control epithelium (P < 0.05).
  • TSPAN1 protein expression in colorectal cancerous tissue was significantly correlated with the histological grade, cell expression PCNA, lymph nodal metastasis and TNM staging of the disease.
  • Furthermore, by multivariate analysis, TSPAN1 protein expression demonstrated an independent prognostic factor for human colorectal cancers (P < 0.05, relative risk 0.755; 95% confidence interval 0.302-1.208).
  • CONCLUSION: The expression of TSPAN1 gene is increased in colorectal carcinoma, suggesting that TSPAN1 might serve as an independent prognostic factor for the colorectal adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Biomarkers, Tumor. Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Membrane Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 2000 Mar 16;1478(1):159-63 [10719184.001]
  • [Cites] Tumori. 2008 Jul-Aug;94(4):531-8 [18822690.001]
  • [Cites] Am J Gastroenterol. 2000 Jun;95(6):1576-80 [10894600.001]
  • [Cites] J Clin Pathol. 2002 Jan;55(1):17-21 [11825918.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):771-5 [12115476.001]
  • [Cites] Oncogene. 2002 Oct 3;21(44):6740-50 [12360401.001]
  • [Cites] J Cancer Epidemiol Prev. 2002;7(3):143-6 [12665213.001]
  • [Cites] Ann Oncol. 2003 Jul;14(7):1026-38 [12853343.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):3-27 [15221985.001]
  • [Cites] Rom J Gastroenterol. 2004 Sep;13(3):223-31 [15470536.001]
  • [Cites] Histopathology. 1981 Mar;5(2):141-63 [7216178.001]
  • [Cites] J Biol Chem. 1988 Jul 25;263(21):10175-9 [2899075.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2313-7 [8941000.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Aug;7(8):661-6 [9718217.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):527-31 [10203586.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):59-68 [16118624.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1261-9 [16799479.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):331-8 [17277767.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):159-66 [17361204.001]
  • [Cites] Int J Surg Pathol. 2007 Oct;15(4):346-53 [17913940.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • (PMID = 19437569.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / TSPAN1 protein, human; 0 / Tetraspanins
  • [Other-IDs] NLM/ PMC2682244
  •  go-up   go-down


53. Kosmidis C, Efthimiadis C, Levva S, Anthimidis G, Baka S, Grigoriou M, Tzeveleki I, Masmanidou M, Zaramboukas T, Basdanis G: Synchronous colorectal adenocarcinoma and gastrointestinal stromal tumor in Meckel's diverticulum; an unusual association. World J Surg Oncol; 2009;7:33
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous colorectal adenocarcinoma and gastrointestinal stromal tumor in Meckel's diverticulum; an unusual association.
  • BACKGROUND: Coexistence of gastrointestinal stromal tumor with synchronous or metachronous colorectal cancer represents a phenomenon with increasing number of relative reports in the last 5 years.
  • We herein report a case of GIST in Meckel's diverticulum synchronous with colorectal adenocarcinoma.
  • Colonoscopy revealed colorectal cancer and a low anterior resection was performed, during which a tumor in Meckel's diverticulum was discovered.
  • Histologic examination revealed GIST in Meckel's diverticulum and a rectosigmoid adenocarcinoma.
  • Correct diagnosis of synchronous tumors of different origin is the cornerstone of treatment.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Gastrointestinal Stromal Tumors / pathology. Meckel Diverticulum / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2002;37(11):947-53 [12483251.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii35-8 [18456761.001]
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):507-19 [6625048.001]
  • [Cites] Magy Onkol. 2004;48(4):315-21 [15655577.001]
  • [Cites] Cancer Control. 2005 Jan-Feb;12(1):44-56 [15668652.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):477-89 [16625094.001]
  • [Cites] World J Gastroenterol. 2006 Sep 7;12(33):5360-2 [16981268.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1466-78 [17090188.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):120-9 [17193825.001]
  • [Cites] World J Surg Oncol. 2007;5:50 [17498311.001]
  • [Cites] Gastroenterol Clin Biol. 2007 Jun-Jul;31(6-7):579-84 [17646784.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):682-6 [10782147.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):318-9 [11231473.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):669-76 [12152168.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Sep;17(9):1033-6 [12167128.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):831-9 [12417503.001]
  • [Cites] Cancer Res. 1970 Feb;30(2):455-65 [5458974.001]
  • (PMID = 19309498.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2664807
  •  go-up   go-down


54. Guo Q, Tang W, Inagaki Y, Midorikawa Y, Kokudo N, Sugawara Y, Nakata M, Konishi T, Nagawa H, Makuuchi M: Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol; 2006 Jan 7;12(1):54-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues.
  • AIM: To assess subcellular localization of KL-6 mucin and its clinicopathological significance in colorectal carcinoma as well as metastatic lymph node and liver tissues.
  • METHODS: Colorectal carcinoma tissues as well as metastatic lymph node and liver tissues were collected from 82 patients who underwent colorectomy or hepatectomy.
  • RESULTS: Of the 82 colorectal carcinoma patients, 6 showed no staining, 29 showed positive staining only in the apical membrane, and 47 showed positive staining in the circumferential membrane and/or cytoplasm.
  • Positive staining was not observed in non-cancerous colorectal epithelial cells surrounding the tumor tissues.
  • Positive staining was observed in all metastatic lesions tested as well as in the primary colorectal carcinoma tissues.
  • CONCLUSION: The subcellular staining pattern of KL-6 in colorectal adenocarcinoma may be an important indicator for unfavorable behaviors such as lymph node and liver metastasis, as well as for the prognosis of patients.
  • [MeSH-major] Adenocarcinoma / chemistry. Antigens / analysis. Colorectal Neoplasms / chemistry. Glycoproteins / analysis. Mucins / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1988 Mar 25;263(9):4215-22 [3346246.001]
  • [Cites] World J Gastroenterol. 2005 Sep 21;11(35):5450-4 [16222735.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15286-93 [1697589.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):455-9 [10675475.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Mar;278(3):L625-9 [10710536.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):1973-82 [11391575.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] World J Gastroenterol. 2001 Jun;7(3):425-30 [11819805.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 17;293(4):1183-90 [12054500.001]
  • [Cites] Histopathology. 2003 Mar;42(3):239-45 [12605643.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5011-20 [12941828.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] World J Gastroenterol. 2004 Oct 15;10(20):3044-7 [15378790.001]
  • [Cites] Hybridoma. 1984 Fall;3(3):223-32 [6094338.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15294-9 [2394722.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1113-23 [2045853.001]
  • [Cites] Cancer Res. 1992 Apr 15;52(8):2318-24 [1559234.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2563-8 [1373671.001]
  • [Cites] Cancer. 1993 Apr 1;71(7):2191-9 [8384065.001]
  • [Cites] Gastroenterology. 1994 Feb;106(2):353-61 [7905449.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):337-42 [8106621.001]
  • [Cites] J Cell Biol. 1995 Apr;129(1):255-65 [7698991.001]
  • [Cites] Annu Rev Physiol. 1995;57:607-34 [7778880.001]
  • [Cites] J Surg Oncol. 1996 Jul;62(3):171-6 [8667623.001]
  • [Cites] Nat Med. 1998 Jan;4(1):43-9 [9427605.001]
  • [Cites] Oncology. 1998 Jul-Aug;55(4):307-19 [9663420.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1262-72 [9788390.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):67-71 [15782996.001]
  • [Cites] Jpn J Clin Oncol. 1988 Sep;18(3):203-16 [3411786.001]
  • (PMID = 16440417.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins
  • [Other-IDs] NLM/ PMC4077483
  •  go-up   go-down


55. Shotar AM: P53 and heat shock protein 70 expressions in colorectal adenocarcinoma. Saudi Med J; 2005 Oct;26(10):1602-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P53 and heat shock protein 70 expressions in colorectal adenocarcinoma.
  • OBJECTIVE: To examine the localization and over expression of heat shock protein 70 (HSP70) and p53 in patients with colorectal cancer and compared it with control tissue (including normal colon tissue).
  • METHODS: This was a retrospective study of 60 patients with colorectal adenocarcinoma at the Jordan University of Science and Technology (JUST), Irbid, Jordan from 1997 to 2000.
  • RESULTS: The HSP70 was over expressed more highly in colorectal cancers than in the control tissue.
  • Control tissue (normal colon) was negative, p53, cell-cycle-related oncogene product, was strongly over expressed in the nuclei of the cancer cells of the cancer tissue.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Colorectal Neoplasms / pathology. HSP70 Heat-Shock Proteins / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16228064.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HSP70 Heat-Shock Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


56. Johnson EE, Leverson GE, Pirsch JD, Heise CP: A 30-year analysis of colorectal adenocarcinoma in transplant recipients and proposal for altered screening. J Gastrointest Surg; 2007 Mar;11(3):272-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 30-year analysis of colorectal adenocarcinoma in transplant recipients and proposal for altered screening.
  • However, the incidence and specific risk for colorectal adenocarcinoma, although previously proposed, has been difficult to calculate.
  • We reviewed the University of Wisconsin transplant database for all cases of colorectal adenocarcinoma to assess the risk of this malignancy, as well as the need for improved screening in this population.
  • METHODS: The transplant database was queried using diagnosis codes for colorectal adenocarcinoma to configure a list of eligible patients.
  • Exclusion criteria included: age less than 18 years at the time of transplant, diagnosis of colorectal cancer or patient death less than 12 months posttransplant, and pretransplant history of colorectal cancer or proctocolectomy.
  • We identified 40 cases of colorectal adenocarcinoma.
  • The median survival postcancer diagnosis was 2.3 years.
  • These results were compared to the National Cancer Institute Survival, Epidemiology, and End Results (SEER) database for colon and rectal cancer.
  • The 5-year survival postcancer diagnosis is 63.5% in the general population (SEER), vs. 30.7% in the transplant cohort.
  • The SEER median age at diagnosis of colorectal adenocarcinoma is 72.0 years.
  • Of the transplant recipients who developed cancer, the median age at diagnosis was 58.7 years (32.4 to 78.2), and 11 patients (27%) were diagnosed at or before age 50.
  • In the U.S. population, the annual incidence of colorectal adenocarcinoma below the age of 50 is 0.0055% (5.52/100,000) and the 10-year extrapolated incidence is 0.11%.
  • In this under-50 cohort, median time from transplant to cancer diagnosis was 7.8 years.
  • CONCLUSION: The incidence of and 5-year survival after diagnosis of colorectal adenocarcinoma in transplant recipients is markedly different than the general population.
  • We propose modifying these guidelines to allow earlier detection of colorectal cancer in this population.
  • [MeSH-major] Adenocarcinoma / etiology. Colorectal Neoplasms / etiology. Organ Transplantation / adverse effects

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17458597.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Liu XP, Shen J, Li ZF, Yan L, Gu J: A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry. Cancer Invest; 2006 Dec;24(8):747-53
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry.
  • PURPOSE: New serum biomarkers are needed to improve the early detection of colorectal adenocarcinoma.
  • We performed surface enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS) to screen for differentially expressed proteins in serum and build a proteomic diagnostic pattern for the detection of colorectal adenocarcinoma to improve the prognosis of patients with this disease.
  • EXPERIMENTAL DESIGN: In an attempt to improve current approaches to the serologic diagnosis of colorectal cancer, we analyzed serum samples from subjects with or without colorectal cancer using SELDI-MS.
  • Using a case-control study design, SELDI-MS profile of serum samples from 74 colorectal adenocarcinoma patients were compared with 48 age-and sex-matched healthy subjects using a ProteinChip reader, PBSII-C.
  • Proteomic MS spectra were generated using IMAC3 chips, and protein peaks clustering and classification analyses were performed to build a proteomic pattern that could differentiate patients with colorectal adenocarcinoma from healthy subjects utilizing Biomarker Wizard and Biomarker Patterns software packages, respectively.
  • The constructed pattern was then used to test an independent set of masked serum samples from 60 colorectal cancer patients and 39 healthy subjects.
  • Masked analysis of an independent set of serum samples showed the diagnostic pattern could differentiate patients with different stages of colorectal cancer from healthy subjects with a sensitivity of 95.00 percent and specificity of 94.87 percent.
  • CONCLUSION: SELDI-TOF-MS profiling of serum proteins combined with bioinformatics tools can be applied to accurately differentiate patients with colorectal cancer from healthy subjects.
  • The high sensitivity and specificity achieved by the constructed clustering analysis algorithm show great potential for the early detection of colorectal cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / blood. Colorectal Neoplasms / diagnosis. Neoplasm Proteins / blood. Proteomics / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162557.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


58. Tanaka S, Saito K, Ito T, Tajima K, Mogi A, Shitara Y, Sano T, Kuwano H: CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens. Oncol Rep; 2007 Jul;18(1):87-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens.
  • Although distinguishing metastatic colorectal adenocarcinoma from primary lung adenocarcinoma is often difficult, pre- or intra-operative identification is very important, as the resection areas for each diagnosis differ substantially.
  • CDX2, a recently cloned homeobox gene, represents a highly specific and sensitive marker of colorectal adenocarcinoma.
  • The study examined 50 consecutive colorectal adenocarcinoma metastases to the lung, including 20 biopsy specimens and 66 resected specimens, and 21 primary lung adenocarcinomas.
  • If CDX2 immunostaining had not been performed, 8 biopsy specimens (40%), and 20 resected specimens (30.3%) might have been diagnosed as equivocal cases either as primary lung cancer or metastatic colorectal cancer, using other markers.
  • These results suggest that positive CDX2 staining represents a highly sensitive and specific marker of metastatic colorectal carcinoma in both biopsy and resected specimens, and is superior to staining for the CK7-/20+ phenotype.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Homeodomain Proteins / metabolism. Lung Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549351.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


59. Badvie S, Hanna-Morris A, Andreyev HJ, Cohen P, Saini S, Allen-Mersh TG: A "field change" of inhibited apoptosis occurs in colorectal mucosa adjacent to colorectal adenocarcinoma. J Clin Pathol; 2006 Sep;59(9):942-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A "field change" of inhibited apoptosis occurs in colorectal mucosa adjacent to colorectal adenocarcinoma.
  • BACKGROUND: Colorectal cancer is associated with a "field change" of increased proliferation throughout the colonic and rectal mucosa.
  • AIM: To determine whether Bcl-xL inhibition of apoptosis is increased in colorectal mucosa adjacent to colorectal adenocarcinoma over that in normal non-neoplastic colorectal mucosa.
  • PATIENTS: PATIENTS undergoing surgical resection for neoplastic (adenocarcinoma) or non-neoplastic disease of the colorectum (rectal prolapse, diverticular disease or volvulus).
  • METHODS: Formalin-fixed, paraffin-wax-embedded surgical colorectal resection specimens were immunostained for Bcl-xL protein.
  • It occurred in a minority of samples from non-neoplastic colorectal mucosa, but was seen in most mucosal samples adjacent to colorectal adenocarcinoma.
  • Significant increases (p<0.001) were observed in Bcl-xL labelling indices in the mucosa at 1 cm (n = 46, median labelling index 31.8%, interquartile range 8.3-43.9%) and at 10 cm (n = 52, median labelling index 22.0%, interquartile range 0.0-36.3%) from colorectal carcinoma, compared with normal, non-neoplastic colorectal mucosa (n = 22, median labelling index 0.0%, interquartile range 0.0-0.0%).
  • CONCLUSIONS: The findings are consistent with a field change of inhibited apoptosis in mucosa adjacent to colorectal carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1987 Mar;92(3):704-8 [3817391.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):4121-6 [3383201.001]
  • [Cites] Nature. 1988 Sep 29;335(6189):440-2 [3262202.001]
  • [Cites] J Clin Pathol. 1990 Sep;43(9):744-7 [2212066.001]
  • [Cites] J Clin Pathol. 2002 Mar;55(3):206-11 [11896073.001]
  • [Cites] Cell. 1993 Aug 27;74(4):597-608 [8358789.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Oct-Nov;3(7):597-605 [7827591.001]
  • [Cites] Dig Dis Sci. 1998 Dec;43(12):2641-8 [9881495.001]
  • [Cites] Gut. 2001 Jan;48(1):41-6 [11115821.001]
  • [Cites] Gut. 1992 Apr;33(4):524-9 [1316306.001]
  • (PMID = 16679352.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / Neoplasm Proteins; 0 / bcl-X Protein
  • [Other-IDs] NLM/ PMC1860481
  •  go-up   go-down


60. Mukaide H, Adachi Y, Taketani S, Iwasaki M, Koike-Kiriyama N, Shigematsu A, Shi M, Yanai S, Yoshioka K, Kamiyama Y, Ikehara S: FKBP51 expressed by both normal epithelial cells and adenocarcinoma of colon suppresses proliferation of colorectal adenocarcinoma. Cancer Invest; 2008 May;26(4):385-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FKBP51 expressed by both normal epithelial cells and adenocarcinoma of colon suppresses proliferation of colorectal adenocarcinoma.
  • It has been reported, as a result of Western blot analyses, that FKBP51 is expressed in various tissues, but that it is not expressed in the pancreas, lung, colon, stomach, or spleen.
  • In this paper, we show, using Western blot analyses, reverse transcriptase polymerase chain reaction, and immunohistochemical analyses of samples from colon cancer patients, that both normal epithelial cells and adenocarcinoma in the human colon express FKBP51, and that there are no significant differences in the expressions of FKBP51 between them.
  • We also show that FKBP51 suppresses the proliferation of colorectal adenocarcinoma, possibly due to the suppression of functions of the glucocorticoid receptors.
  • [MeSH-major] Adenocarcinoma / metabolism. Colon / metabolism. Colorectal Neoplasms / metabolism. Neoplasm Proteins / physiology. Tacrolimus Binding Proteins / physiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • Hazardous Substances Data Bank. MIFEPRISTONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443959.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / RNA, Small Interfering; 0 / Receptors, Glucocorticoid; 320T6RNW1F / Mifepristone; EC 5.2.1.- / Tacrolimus Binding Proteins; EC 5.2.1.8 / tacrolimus binding protein 5; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


61. Chen YJ, Liao HF, Tsai TH, Wang SY, Shiao MS: Caffeic acid phenethyl ester preferentially sensitizes CT26 colorectal adenocarcinoma to ionizing radiation without affecting bone marrow radioresponse. Int J Radiat Oncol Biol Phys; 2005 Nov 15;63(4):1252-61
Hazardous Substances Data Bank. 2-PHENYLETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caffeic acid phenethyl ester preferentially sensitizes CT26 colorectal adenocarcinoma to ionizing radiation without affecting bone marrow radioresponse.
  • METHODS AND MATERIALS: The effects of CAPE on GSH level, GSH metabolism enzyme activities, NF-kappaB activity, and radiosensitivity in mouse CT26 colorectal adenocarcinoma cells were determined.
  • CONCLUSIONS: CAPE sensitizes CT26 colorectal adenocarcinoma to IR, which may be via depleting GSH and inhibiting NF-kappaB activity, without toxicity to bone marrow, liver, and kidney.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Bone Marrow / radiation effects. Caffeic Acids / pharmacology. Colorectal Neoplasms / radiotherapy. Phenylethyl Alcohol / analogs & derivatives. Radiation-Sensitizing Agents / pharmacology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253780.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caffeic Acids; 0 / NF-kappa B; 0 / Radiation-Sensitizing Agents; EC 1.11.1.9 / Glutathione Peroxidase; EC 2.3.2.2 / gamma-Glutamyltransferase; G960R9S5SK / caffeic acid phenethyl ester; GAN16C9B8O / Glutathione; ML9LGA7468 / Phenylethyl Alcohol
  •  go-up   go-down


62. Yoo PS, Sullivan CA, Kiang S, Gao W, Uchio EM, Chung GG, Cha CH: Tissue microarray analysis of 560 patients with colorectal adenocarcinoma: high expression of HuR predicts poor survival. Ann Surg Oncol; 2009 Jan;16(1):200-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue microarray analysis of 560 patients with colorectal adenocarcinoma: high expression of HuR predicts poor survival.
  • The purpose of this study is to characterize the expression of HuR in colorectal carcinoma and determine its correlation with clinical outcome.
  • A tissue microarray consisting of tumors from 560 patients with colorectal adenocarcinoma was analyzed for HuR protein expression using a quantitative, automated immunofluorescent microscopy system (AQUA).
  • We conclude that expression of high levels of HuR correlates with features of advanced disease and portends poorer survival in patients with colorectal adenocarcinoma.
  • These results further suggest that HuR exerts its tumorigenic effects through VEGF-mediated angiogenesis and may be a novel therapeutic target in colorectal cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Surface / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. RNA-Binding Proteins / metabolism. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19009247.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, Surface; 0 / Biomarkers, Tumor; 0 / ELAV Proteins; 0 / ELAV-Like Protein 1; 0 / ELAVL1 protein, human; 0 / RNA-Binding Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


63. Georgescu SO, Neacşu CN, Vintilă D, Popa P, Forţu L, Nistor A, Ferariu D, Târcoveanu E: [Long-term results after surgery for colorectal adenocarcinoma, stage I-III. Problems of prognosis]. Rev Med Chir Soc Med Nat Iasi; 2007 Oct-Dec;111(4):932-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results after surgery for colorectal adenocarcinoma, stage I-III. Problems of prognosis].
  • [Transliterated title] Rezultate la distanţă după tratamentul chirurgical al adenocarcinomului colo-rectal stadiile I-III. Probleme de prognostic.
  • Colorectal cancer is one of the leading causes of cancer-related death worldwide.
  • STUDY DESIGN: Prospective study on 142 consecutively cases with stage I to III colorectal adenocarcinomas (TNM AJCC/UICC) in which patients underwent potentially curative surgery in one single public health service (1st Surgical Clinic Iaşi, Romania) between 2004 and 2005.
  • The surgical procedures performed were the following: right colectomy (n = 54; 30%); transverse colectomy (n = 2; 1.4%); left colectomy (n = 19; 13.4%); segmental colon resection with anastomosis (n = 5 ; 3.5%); Hartmann procedure (n = 18; 12.7%); anterior rectal resection (n = 11; 7.7%) and abdominoperineal resection (n = 33; 23.2%).
  • RESULTS: The factors with a significant negative influence in overall survival and 42-months survival rates were: the age over 70 years, the emergency surgery related to cancer's complications, the advanced AJCC/ UICC stage, vascular invasion, perineural invasion, the recurrence of disease, the moderate and lower differentiated adenocarcinoma and incomplete or not performed chemotherapy.
  • CONCLUSION: Even with a radical surgical approach the advanced stage of colorectal adenocarcinoma has a low prognostic, but some other factors have also a high significance in postoperative outcome.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Colectomy / methods. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18389783.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


64. Quadros CA, Lopes A, Araujo I: Suggestion of optimal patient characteristics for sentinel lymph node mapping in colorectal adenocarcinoma. Arq Gastroenterol; 2010 Oct-Dec;47(4):344-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suggestion of optimal patient characteristics for sentinel lymph node mapping in colorectal adenocarcinoma.
  • CONTEXT: In a previously published study, the variables lower rectal tumor site, preoperative chemoradiotherapy and large tumors were considered as independent risk factors for the inability of sentinel lymph node identification in patients with colorectal adenocarcinoma.
  • OBJECTIVES: To determine if these variables could interfere in the precision and upstaging benefit of sentinel lymph node mapping in colorectal cancer.
  • CONCLUSION: The parameters proposed in this study for selection of colorectal adenocarcinoma patients to be submitted to sentinel lymph node mapping identified optimal accuracy and good upstaging results.
  • As the number of included patients was low, these results could serve as guidance for proper patient selection in further prospective lymph node mapping studies in colorectal cancer patients.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21225143.001).
  • [ISSN] 1678-4219
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium phytate; 7IGF0S7R8I / Phytic Acid
  •  go-up   go-down


65. Gonçalves I, Linhares M, Bordin J, Matos D: Risk factors for indications of intraoperative blood transfusion among patients undergoing surgical treatment for colorectal adenocarcinoma. Arq Gastroenterol; 2009 Jul-Sep;46(3):190-3
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for indications of intraoperative blood transfusion among patients undergoing surgical treatment for colorectal adenocarcinoma.
  • CONTEXT: Identification of risk factors for requiring transfusions during surgery for colorectal cancer may lead to preventive actions or alternative measures, towards decreasing the use of blood components in these procedures, and also rationalization of resources use in hemotherapy services.
  • This was a retrospective case-control study using data from 383 patients who were treated surgically for colorectal adenocarcinoma at 'Fundação Pio XII', in Barretos-SP, Brazil, between 1999 and 2003.
  • OBJECTIVE: To recognize significant risk factors for requiring intraoperative blood transfusion in colorectal cancer surgical procedures.
  • CONCLUSION: This investigation allows the conclusion that radical intervention and the abdominoperineal procedure in the surgical treatment of colorectal adenocarcinoma are risk factors for requiring intraoperative blood transfusion.
  • [MeSH-major] Blood Transfusion. Colorectal Neoplasms / surgery. Intraoperative Care

  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19918684.001).
  • [ISSN] 1678-4219
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


66. Köbel M, Budianto D, Schmitt WD, Borsi L, Siri A, Hauptmann S: Influence of various cytokines on adhesion and migration of the colorectal adenocarcinoma cell line HRT-18. Oncology; 2005;68(1):33-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of various cytokines on adhesion and migration of the colorectal adenocarcinoma cell line HRT-18.
  • The stroma of colorectal adenocarcinoma contains both abundant extracellular matrix (ECM) and an inflammatory cell infiltrate.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Cytokines / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15809518.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cytokines; 0 / Fibronectins; 0 / Tenascin; 9007-34-5 / Collagen
  •  go-up   go-down


67. Cardoso ML, Fernandes LC, Kim SB, Matos D: Relationship between peripheral and mesenteric serum levels of CEA and CA 242 with staging and histopathological variables in colorectal adenocarcinoma. Acta Cir Bras; 2009 Sep-Oct;24(5):405-10
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between peripheral and mesenteric serum levels of CEA and CA 242 with staging and histopathological variables in colorectal adenocarcinoma.
  • PURPOSE: To compare histopathological variables and staging in colorectal adenocarcinoma cases with CEA and CA 242 in peripheral and mesenteric blood.
  • METHODS: In 169 individuals underwent surgery for colorectal cancer, CEA and CA 242 were analyzed and compared to mesenteric and peripheral blood and correlated with macroscopic tumor's morphology and size, degree of cell differentiation, venous, neural and lymphatic involvement and TNM classification.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19851695.001).
  • [ISSN] 1678-2674
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / CA 242 antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


68. Petty RD, Samuel LM, Murray GI, MacDonald G, O'Kelly T, Loudon M, Binnie N, Aly E, McKinlay A, Wang W, Gilbert F, Semple S, Collie-Duguid ES: APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. BMC Cancer; 2009;9:434
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.
  • BACKGROUND: 5-Fluorouracil(5FU) and oral analogues, such as capecitabine, remain one of the most useful agents for the treatment of colorectal adenocarcinoma.
  • We investigated the molecular mechanisms of clinical 5FU resistance in colorectal adenocarcinoma patients in a prospective biomarker discovery project utilising gene expression profiling.
  • METHODS: Putative treatment specific gene expression changes were identified in a transcriptomics study of rectal adenocarcinomas, biopsied and profiled before and after pre-operative short-course radiotherapy or 5FU based chemo-radiotherapy, using microarrays.
  • Tumour from untreated controls at diagnosis and resection identified treatment-independent gene expression changes.
  • Candidate 5FU chemo-resistant genes were identified by comparison of gene expression data sets from these clinical specimens with gene expression signatures from our previous studies of colorectal cancer cell lines, where parental and daughter lines resistant to 5FU were compared.
  • A colorectal adenocarcinoma tissue microarray (n = 234, resected tumours) was used as an independent set to qualify candidates thus identified.
  • RESULTS: APRIL/TNFSF13 mRNA was significantly upregulated following 5FU based concurrent chemo-radiotherapy and in 5FU resistant colorectal adenocarcinoma cell lines but not in radiotherapy alone treated colorectal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. Drug Resistance, Neoplasm / genetics. Tumor Necrosis Factor Ligand Superfamily Member 13 / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1021-7 [10706119.001]
  • [Cites] Oncology (Williston Park). 2008 Nov 30;22(13):1470-9 [19133603.001]
  • [Cites] J Exp Med. 2000 Dec 4;192(11):1677-84 [11104810.001]
  • [Cites] Cell Death Differ. 2001 Apr;8(4):403-10 [11550092.001]
  • [Cites] J Clin Invest. 2002 Jun;109(12):1587-98 [12070306.001]
  • [Cites] Int J Oncol. 2002 Oct;21(4):787-93 [12239617.001]
  • [Cites] Int J Oncol. 2002 Dec;21(6):1223-8 [12429971.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):311-24 [12787568.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4602-6 [12907638.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3391-401 [12885834.001]
  • [Cites] Blood. 2004 Jan 15;103(2):679-88 [14504101.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):3005-12 [14691452.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6635-40 [15096622.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2A):417-23 [15152939.001]
  • [Cites] Nucleic Acids Res. 2004;32(16):4786-803 [15356296.001]
  • [Cites] J Pathol. 2004 Oct;204(2):183-92 [15378567.001]
  • [Cites] Dis Colon Rectum. 1998 Jan;41(1):68-74 [9510313.001]
  • [Cites] J Exp Med. 1998 Sep 21;188(6):1185-90 [9743536.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1641-9 [15547701.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8167-76 [15548681.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):732-40 [15681518.001]
  • [Cites] Virchows Arch. 2005 Feb;446(2):127-35 [15602683.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1826-38 [15774776.001]
  • [Cites] Radiat Res. 2005 Oct;164(4 Pt 2):523-6 [16187761.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1729-44 [16549823.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):921-7 [16953238.001]
  • [Cites] BMJ. 2006 Oct 14;333(7572):779 [16984925.001]
  • [Cites] Biochim Biophys Acta. 2006 Dec;1766(2):184-96 [16973289.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):839-45 [17119966.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3230-7 [17664471.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4329-36 [17906194.001]
  • [Cites] Molecules. 2008;13(8):1551-69 [18794772.001]
  • [Cites] Eur J Cancer. 2008 Oct;44(15):2097-100 [18718755.001]
  • [Cites] Dis Colon Rectum. 2000 Apr;43(4):451-9 [10789738.001]
  • (PMID = 20003335.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0701127
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Tumor Necrosis Factor Ligand Superfamily Member 13; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2801520
  •  go-up   go-down


69. Delektorskaya VV, Perevoshchikov AG, Golovkov DA, Kushlinskii NE: Expression of E-cadherin, beta-catenin, and CD-44v6 cell adhesion molecules in primary tumors and metastases of colorectal adenocarcinoma. Bull Exp Biol Med; 2005 Jun;139(6):706-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of E-cadherin, beta-catenin, and CD-44v6 cell adhesion molecules in primary tumors and metastases of colorectal adenocarcinoma.
  • Immunohistochemical analysis of the expression of E-cadherin, beta-catenin, and CD-44v6 proteins was carried out for evaluating the metastatic potential of colorectal cancer cells.
  • Specific features of expression, distribution, and interactions of adhesive molecules in primary tumors of the large intestine and their metastases in the liver and lymph nodes were studied.
  • Reduction and complete absence of E-cadherin expression were much more often observed in patients with colorectal cancer with metastases in the liver than in patients without metastases.
  • Cytoplasmic immunoreactivity and nuclear translocation of beta-catenin were increased in more than 80% cases with colorectal adenocarcinoma with metastases.
  • These changes in the expression of E-cadherin and beta-catenin in tumor cells can be regarded as factors of unfavorable prognosis of colorectal cancer.
  • [MeSH-major] Antigens, CD44 / metabolism. Cadherins / metabolism. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Lymph Nodes / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Cell Adhesion Molecules / metabolism. Chi-Square Distribution. Female. Follow-Up Studies. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis / genetics. Neoplasm Metastasis / pathology. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224588.001).
  • [ISSN] 0007-4888
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / beta Catenin
  •  go-up   go-down


70. Zhang Z, Deng X, Ren X, Zhang B, Chen X, Yang J, Ding H, Sui J, Song X: Expression of mutant p53 and of the multidrug resistant proteins P-glycoprotein and glutathione S-transferase-pi correlated in colorectal adenocarcinoma. Scand J Gastroenterol; 2010 Aug;45(7-8):925-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of mutant p53 and of the multidrug resistant proteins P-glycoprotein and glutathione S-transferase-pi correlated in colorectal adenocarcinoma.
  • This study was to estimate mutant p53 expression and its correlation with drug resistance related proteins Pgp and GST-pi expression in colorectal adenocarcinoma patients.
  • MATERIAL AND METHODS: Immunohistochemical ABC technique was used to detect the expression of mutant p53 protein, Pgp and GST-pi in 404 cases with colorectal adenocarcinoma.
  • RESULTS: A low frequency of mutant p53 accumulation was observed, consistent with findings in colorectal cancers (CRCs) from other Asian populations.
  • CONCLUSIONS: These findings demonstrate association of three biomarkers with clinicopathologic parameters of colorectal carcinoma, and overexpression of Pgp and GST-pi was closely correlated with mutant p53.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Drug Resistance, Multiple / genetics. Gene Expression Regulation, Neoplastic. Genes, p53 / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377486.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / P-Glycoprotein; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


71. Saltzstein SL, Behling CA: Age and time as factors in the left-to-right shift of the subsite of colorectal adenocarcinoma: a study of 213,383 cases from the California Cancer Registry. J Clin Gastroenterol; 2007 Feb;41(2):173-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age and time as factors in the left-to-right shift of the subsite of colorectal adenocarcinoma: a study of 213,383 cases from the California Cancer Registry.
  • GOALS: Using a data set of more than 200,000 cases, we can measure the effects of age, time, sex, and race/ethnicity on the shift of the site of origin of colorectal adenocarcinoma from the left to the right side.
  • BACKGROUND: As people become older, there is a shift of the site of origin of adenocarcinoma of the colorectum from the left to the right side.
  • Although some studies do show some relationship of this shift, in addition to age, to race/ethnicity and to sex, there are no large, total population-based data studying the effects of these factors and time trends in this shift.
  • STUDY: 213,383 cases of adenocarcinoma of the colorectum for the years 1988 to 2003 from the California Cancer Registry have been studied.
  • RESULTS: The left-to-right shift increases significantly with increasing age and year of diagnosis, and is greater in women than in men and is greater in whites than in other racial/ethnic groups.
  • The time-related shift is a reflection of a lesser decrease in the incidence of colorectal adenocarcinoma on the right side than on the left.
  • [MeSH-major] Adenocarcinoma / pathology. Aging. Colorectal Neoplasms / pathology. Registries

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17245216.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


72. Welsh JS, Kennedy AS, Thomadsen B: Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. Int J Radiat Oncol Biol Phys; 2006;66(2 Suppl):S62-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma.
  • It is FDA approved for liver metastases secondary to colorectal carcinoma and is under investigation for treatment of other liver malignancies, such as hepatocellular carcinoma and neuroendocrine malignancies.
  • CONCLUSIONS: Selective internal radiation therapy represents an effective means of controlling liver metastases from colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Colorectal Neoplasms. Liver Neoplasms / radiotherapy. Yttrium Radioisotopes / therapeutic use

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979443.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Technetium Tc 99m Aggregated Albumin; 0 / Yttrium Radioisotopes
  • [Number-of-references] 70
  •  go-up   go-down


73. Jin JS, Wu CY, Lin YF, Wang JY, Yu CP, Sheu LF, Chiang H, Tsai WC, Lee WH: Higher expression of epidermal growth factor receptor is associated with extracellular matrix metalloprotease inducer in colorectal adenocarcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Dis Markers; 2006;22(5-6):309-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher expression of epidermal growth factor receptor is associated with extracellular matrix metalloprotease inducer in colorectal adenocarcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters.
  • AIM: Extracellular matrix metalloprotease inducer (EMMPRIN) expression was demonstrated in several cancers, but its expression profile in colorectal cancers remains unclear.
  • Our purpose was to determine EMMPRIN expression and its relationship with EGFR in colorectal cancers.
  • METHODS: Immunohistochemical analysis of EMMPRIN and EGFR was performed in tissue microarray slides of 90 surgical specimens including 32 well differentiated, 35 moderately differentiated, and 23 poorly differentiated colorectal adenocarcinomas.
  • RESULTS: All colorectal adenocarcinomas showed significant immunohistochemical expression of EMMPRIN.
  • The EMMPRIN scores in poorly differentiated (303 +/- 21) and moderately differentiated (326 +/- 17) colorectal adenocarcinoma were significantly higher than in well differentiated (166 +/- 20) colorectal adenocarcinoma.
  • CONCLUSIONS: Increased expression of EMMPRIN and EGFR in colorectal adenocarcinomas is associated with clinicopathological parameters of advanced colorectal adenocarcinoma stages.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, CD147 / analysis. Colorectal Neoplasms / diagnosis. Receptor, Epidermal Growth Factor / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264401.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 136894-56-9 / Antigens, CD147; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC3851072
  •  go-up   go-down


74. Bacigalupo L, Aufort S, Eberlé MC, Assenat E, Ychou M, Gallix B: Assessment of liver metastases from colorectal adenocarcinoma following chemotherapy: SPIO-MRI versus FDG-PET/CT. Radiol Med; 2010 Oct;115(7):1087-100
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of liver metastases from colorectal adenocarcinoma following chemotherapy: SPIO-MRI versus FDG-PET/CT.
  • PURPOSE: This study compared superparamagnetic iron-oxide-enhanced magnetic resonance imaging (SPIO-MRI) and combined fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) in evaluating liver metastases from colorectal adenocarcinoma following chemotherapy.
  • CONCLUSIONS: SPIO-MRI appears superior to PET/CT in evaluating liver metastases from colorectal adenocarcinoma following chemotherapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Contrast Media. Ferrosoferric Oxide. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Magnetic Resonance Imaging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20574703.001).
  • [ISSN] 1826-6983
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; XM0M87F357 / Ferrosoferric Oxide
  •  go-up   go-down


75. Yamaguchi T, Takahashi H, Kagawa R, Takeda R, Sakata S, Yamamoto M, Nishizaki D, Iwasa Y: The role of prophylactic bilateral oophorectomy at the time of initial diagnosis of a unilateral ovarian metastasis in cases with colorectal adenocarcinoma. Hepatogastroenterology; 2008 Mar-Apr;55(82-83):434-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of prophylactic bilateral oophorectomy at the time of initial diagnosis of a unilateral ovarian metastasis in cases with colorectal adenocarcinoma.
  • BACKGROUND/AIMS: In cases with a macroscopic unilateral ovarian metastasis of colorectal adenocarcinoma, a clear therapeutic policy regarding a prophylactic bilateral oophorectomy is lacking.
  • METHODOLOGY: Four cases of ovarian metastases of colorectal adenocarcinoma are presented.
  • RESULTS: Case 1 is a 63-year-old with ascending colon carcinoma, Dukes' C, and right oophorectomy due to metachronous ovarian metastasis.
  • Case 2 is a 28-year-old with transverse colon carcinoma, Dukes' D, and right oophorectomy due to synchronous ovarian metastasis.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Colorectal Neoplasms / pathology. Ovarian Neoplasms / secondary. Ovarian Neoplasms / surgery. Ovariectomy / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613382.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


76. Ordóñez A, Yélamos J, Pedersen S, Miñano A, Conesa-Zamora P, Kristensen SR, Stender MT, Thorlacius-Ussing O, Martínez-Martínez I, Vicente V, Corral J: Increased levels of citrullinated antithrombin in plasma of patients with rheumatoid arthritis and colorectal adenocarcinoma determined by a newly developed ELISA using a specific monoclonal antibody. Thromb Haemost; 2010 Dec;104(6):1143-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased levels of citrullinated antithrombin in plasma of patients with rheumatoid arthritis and colorectal adenocarcinoma determined by a newly developed ELISA using a specific monoclonal antibody.
  • We determined the levels of citrullinated antithrombin and anti-FXa activity in plasma from 66 donors, 17 patients with rheumatoid arthritis and 77 patients with colorectal adenocarcinoma (42 suffering from venous thrombosis).
  • Healthy subjects had negligible amounts of citrullinated antithrombin in plasma (7.9 ± 22.1 ng/ml), while it significantly increased in patients with rheumatoid arthritis or adenocarcinoma (159.7 ± 237.6 ng/ml and 36.8 ± 66.1 ng/ml), levels that, however, did not modify the plasma anticoagulant activity.
  • Moreover, we did not find association between citrullinated antithrombin and the thrombotic risk in patients with adenocarcinoma.
  • We confirm increased levels of citrullinated antithrombin in plasma of patients with rheumatoid arthritis and adenocarcinoma.
  • This result explains the absence of association of this marker with an increased risk of thrombosis in patients with colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / blood. Antibodies, Monoclonal / immunology. Antithrombins / blood. Arthritis, Rheumatoid / blood. Citrulline / blood. Colorectal Neoplasms / blood. Enzyme-Linked Immunosorbent Assay

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20838745.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antithrombins; 0 / Biomarkers; 0 / Factor Xa Inhibitors; 29VT07BGDA / Citrulline
  •  go-up   go-down


77. Nakayama T, Hatachi G, Wen CY, Yoshizaki A, Yamazumi K, Niino D, Sekine I: Expression and significance of Tie-1 and Tie-2 receptors, and angiopoietins-1, 2 and 4 in colorectal adenocarcinoma: Immunohistochemical analysis and correlation with clinicopathological factors. World J Gastroenterol; 2005 Feb 21;11(7):964-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and significance of Tie-1 and Tie-2 receptors, and angiopoietins-1, 2 and 4 in colorectal adenocarcinoma: Immunohistochemical analysis and correlation with clinicopathological factors.
  • The objective of this study was to establish a comprehensive Tie-1 and Tie-2 and Ang-1, 2 and 4 expression profile in human colorectal adenocarcinomas.
  • METHODS: We examined 96 cases of surgically resected human colorectal adenocarcinoma by immunohistochemistry and investigated the statistical correlation between the expressions of Ties and Angs and clinicopathological factors.
  • RESULTS: Among the 96 cases of adenocarcinoma, 87 (90.6%), 92 (95.8%), 83 (86.5%), 89 (92.7%), and 76 cases (79.2%) showed positive staining in the cytoplasm of carcinoma cells for the Tie-1 and Tie-2 and Ang-1, 2 and 4 proteins, respectively.
  • Ties and Angs were highly expressed in human colorectal adenocarcinoma cells.
  • CONCLUSION: These findings suggest that the Tie-Ang receptor-ligand complex is one of the factors involved in the cellular differentiation and progression of human colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Angiopoietin-1 / metabolism. Angiopoietin-2 / metabolism. Colorectal Neoplasms / metabolism. Receptor, TIE-1 / metabolism. Receptor, TIE-2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742397.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ANGPT1 protein, human; 0 / Angiopoietin-1; 0 / Angiopoietin-2; 0 / Angiopoietins; 0 / Ligands; 0 / angiopoietin 4; EC 2.7.10.1 / Receptor, TIE-1; EC 2.7.10.1 / Receptor, TIE-2
  • [Other-IDs] NLM/ PMC4250786
  •  go-up   go-down


78. Katkoori VR, Jia X, Chatla C, Kumar S, Ponnazhagan S, Callens T, Messiaen L, Grizzle WE, Manne U: Clinical significance of a novel single nucleotide polymorphism in the 5' untranslated region of the Rabphillin-3A-Like gene in colorectal adenocarcinoma. Front Biosci; 2008 Jan 01;13:1050-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of a novel single nucleotide polymorphism in the 5' untranslated region of the Rabphillin-3A-Like gene in colorectal adenocarcinoma.
  • The recently identified human ortholog of the Rabphillin-3A-Like (RPH3AL) gene, located at the 17p13.3 locus, has been assessed for its mutational status and clinical significance in colorectal adenocarcinoma (CRC).
  • [MeSH-major] 5' Untranslated Regions. Colorectal Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Polymorphism, Single Nucleotide. rab GTP-Binding Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1989 Aug 12;2(8659):353-6 [2569552.001]
  • [Cites] Oncogene. 1999 Aug 12;18(32):4530-7 [10467397.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3391-5 [1596898.001]
  • [Cites] Oncogene. 2002 Jun 27;21(28):4462-70 [12080476.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4992-5 [12208751.001]
  • [Cites] Oncol Rep. 2002 Nov-Dec;9(6):1189-92 [12375017.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1057-65 [12402142.001]
  • [Cites] Jpn J Cancer Res. 2002 Nov;93(11):1221-9 [12460463.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 16;95(14):1044-53 [12865450.001]
  • [Cites] Gut. 2003 Dec;52(12):1756-63 [14633957.001]
  • [Cites] Environ Mol Mutagen. 2003;42(4):299-305 [14673875.001]
  • [Cites] Mol Endocrinol. 2004 Jan;18(1):117-26 [14593078.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] JAMA. 1989 Jun 2;261(21):3099-103 [2654431.001]
  • [Cites] Genomics. 1999 Jul 1;59(1):97-101 [10395805.001]
  • [Cites] Genomics. 1999 Jun 15;58(3):310-2 [10373329.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):93-101 [15459023.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):314-9 [15661214.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):594-9 [15701845.001]
  • [Cites] Head Neck. 2005 Mar;27(3):232-42 [15668931.001]
  • [Cites] Mutat Res. 2005 Jun 6;583(2):120-32 [15876548.001]
  • [Cites] Brain Res Mol Brain Res. 2005 Oct 3;139(2):212-6 [15953657.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8592-9 [16361542.001]
  • [Cites] EMBO J. 2006 Mar 8;25(5):977-86 [16498408.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2698-702 [11226302.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7422-5 [11606374.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1894-9 [11747332.001]
  • [Cites] J Natl Cancer Inst. 2002 May 1;94(9):681-90 [11983757.001]
  • [Cites] J Mol Diagn. 2002 May;4(2):103-7 [11986401.001]
  • [Cites] Int J Colorectal Dis. 2002 Jan;17(1):46-9 [12018454.001]
  • [Cites] Nature. 1994 Jun 9;369(6480):493-7 [7911226.001]
  • [Cites] Genomics. 1994 Sep 1;23(1):229-32 [7829075.001]
  • [Cites] Carcinogenesis. 1995 Sep;16(9):2205-8 [7554076.001]
  • [Cites] Nat Med. 1995 Sep;1(9):902-9 [7585215.001]
  • [Cites] J Neurooncol. 1995;24(1):39-45 [8523074.001]
  • [Cites] J Biol Chem. 1996 Dec 13;271(50):31775-8 [8943213.001]
  • [Cites] Blood. 1997 Jul 15;90(2):678-89 [9226168.001]
  • [Cites] J Biol Chem. 1997 Nov 21;272(47):29407-10 [9367993.001]
  • [Cites] J Biol Chem. 1998 Dec 18;273(51):34580-5 [9852129.001]
  • [Cites] Biotechniques. 1999 Feb;26(2):198-200 [10023524.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • (PMID = 17981610.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098932-05; United States / NCI NIH HHS / CA / U54 CA118623; United States / NCI NIH HHS / CA / U54 CA118948; United States / NCI NIH HHS / CA / R01 CA098932; United States / NCI NIH HHS / CA / R01-CA98932-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5' Untranslated Regions; 0 / RPH3AL protein, human; EC 3.6.5.2 / rab GTP-Binding Proteins
  • [Other-IDs] NLM/ NIHMS100639; NLM/ PMC2667692
  •  go-up   go-down


79. Yuan RH, Wang CC, Chou CC, Chang KJ, Lee PH, Jeng YM: Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol; 2009 Jun;16(6):1711-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma.
  • This study sought to elucidate its role in tumor progression and prognosis of colorectal adenocarcinoma (CRA).
  • Diffuse IMP3 expression correlated with large tumor (>3 cm, P = .0452), high-stage tumor (IIIa-IV, P = .0417), lymph node metastasis (P = .0232), high lymph node ratio (LNR > or = .7, P = .0016), and lower 5-year survival (P = .0012).
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. Neoplasm Proteins / genetics. RNA-Binding Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19357927.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


80. Zhang Y, Ye X, Geng J, Chen L: Epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in gastric and colorectal adenocarcinoma. Hepatogastroenterology; 2010 Nov-Dec;57(104):1614-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in gastric and colorectal adenocarcinoma.
  • BACKGROUND/AIM: Deleted in Lung and Esophageal Cancer 1 (DLEC1) gene was a new candidate tumor suppressor gene, we evaluated the diagnostic role of DLEC1 methylation in gastric adenocarcinoma (GAC) and colorectal adenocarcinoma (CRAC).
  • CONCLUSION: Epigenetic inactivation of DLEC1 was crucial in gastric and colorectal carcinogenesis.
  • DLEC1 methylation in serum may be a promise biomarker for GAC and CRAC early diagnosis.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Promoter Regions, Genetic / genetics. Stomach Neoplasms / genetics. Tumor Suppressor Proteins / genetics


81. Soop M, Nelson H: Is laparoscopic resection appropriate for colorectal adenocarcinoma? Adv Surg; 2008;42:205-17
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is laparoscopic resection appropriate for colorectal adenocarcinoma?
  • Oncologic safety has now been demonstrated for laparoscopy-assisted surgery for colon adenocarcinoma after 3 and 5 years of follow-up.
  • Pooled data from large multicenter and smaller single-center trials demonstrate that the modality conveys significant short-term benefits as compared with open surgery, although the full potential has probably not yet been reached.
  • Currently, the data supports improvements in wound morbidity, intraoperative blood loss, narcotic analgesia requirements, time to resumption of bowel movements, and time to discharge from hospital.
  • There is a large potential for improved short-term results when combined with current and developing enhanced-recovery programs.
  • Data from the first large multicenter trial suggest that laparoscopic dissection may compromise the circumferential resection margin, and this issue will be the focus of ongoing and planned trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953819.001).
  • [ISSN] 0065-3411
  • [Journal-full-title] Advances in surgery
  • [ISO-abbreviation] Adv Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


82. Wilkinson N, Scott-Conner CE: Surgical therapy for colorectal adenocarcinoma. Gastroenterol Clin North Am; 2008 Mar;37(1):253-67, ix
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical therapy for colorectal adenocarcinoma.
  • Colorectal cancer (CRC) remains the second leading cause of cancer mortality among men, and the third leading cause among women.
  • Unfortunately, advanced disease at diagnosis is still all too common.
  • Locally advanced rectal cancer, node-positive colon cancer, and metastatic disease still compose a significant proportion of colon and rectal cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colorectal Neoplasms / surgery. Laparoscopy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313549.001).
  • [ISSN] 0889-8553
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


83. Wu CC, Shyu RY, Chou JM, Jao SW, Chao PC, Kang JC, Wu ST, Huang SL, Jiang SY: RARRES1 expression is significantly related to tumour differentiation and staging in colorectal adenocarcinoma. Eur J Cancer; 2006 Mar;42(4):557-65
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RARRES1 expression is significantly related to tumour differentiation and staging in colorectal adenocarcinoma.
  • This study investigated the clinical significance of RARRES1 protein and its association with RARRES3 protein expression in 161 (26 adenoma, 13 distal normal mucosa and 122 primary colorectal adenocarcinoma) paraffin-embedded colorectal tissues by immunohistochemistry.
  • Among 122 colorectal adenocarcinomas, the poorly differentiated adenocarcinomas and Dukes' stage D tumours showed a significant decrease in RARRES1 expression (P < 0.001 and P < 0.01, respectively).
  • Our results suggest the role of RARRES1 in colorectal epithelial differentiation, and the down-regulation of RARRES1 is related to stage D progression.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Transformation, Neoplastic / metabolism. Colorectal Neoplasms / pathology. Membrane Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426842.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / RARRES1 protein, human; 0 / RARRES3 protein, human; 0 / Receptors, Retinoic Acid
  •  go-up   go-down


84. Karaman A, Binici DN, Kabalar ME, Calikuşu Z: Micronucleus analysis in patients with colorectal adenocarcinoma and colorectal polyps. World J Gastroenterol; 2008 Nov 28;14(44):6835-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micronucleus analysis in patients with colorectal adenocarcinoma and colorectal polyps.
  • AIM: To determine, by counting micronucleus (MN) frequencies, whether chromosomal or DNA damage have an effect on the pathogenesis of early colorectal adenocarcinoma (CRC).
  • METHODS: We analyzed MN frequencies in 21 patients with CRC, 24 patients with colon polyps [10 neoplastic polyps (NP) and 14 non-neoplastic polyps (NNP)] and 20 normal controls.
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. Genomic Instability. Micronuclei, Chromosome-Defective. Precancerous Conditions / genetics

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 2000 Nov 20;455(1-2):81-95 [11113469.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):625-31 [16973674.001]
  • [Cites] Nat Rev Genet. 2001 Mar;2(3):196-206 [11256071.001]
  • [Cites] Curr Opin Oncol. 2000 Jan;12(1):82-8 [10687734.001]
  • [Cites] Mutagenesis. 2000 May;15(3):261-9 [10792021.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):854-65 [10982779.001]
  • [Cites] Nature. 2000 Nov 23;408(6811):433-9 [11100718.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Feb;11(2):167-75 [11867504.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):55-67 [11900252.001]
  • [Cites] Science. 2002 Jul 26;297(5581):552-7 [12142524.001]
  • [Cites] Science. 2002 Jul 26;297(5581):559-65 [12142526.001]
  • [Cites] Science. 2002 Jul 26;297(5581):565-9 [12142527.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16226-31 [12446840.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16910-5 [12486240.001]
  • [Cites] Mutat Res. 2003 Jan 10;534(1-2):65-75 [12504755.001]
  • [Cites] Drug Discov Today. 2002 Nov 15;7(22):1128-37 [12546856.001]
  • [Cites] Cancer Biol Ther. 2002 Nov-Dec;1(6):685-92 [12642695.001]
  • [Cites] Nat Cell Biol. 2003 Mar;5(3):190-2 [12646874.001]
  • [Cites] Curr Biol. 2003 Apr 1;13(7):581-4 [12676089.001]
  • [Cites] Gut. 2003 May;52(5):623-8 [12692043.001]
  • [Cites] Math Biosci. 2003 Jun;183(2):111-34 [12711407.001]
  • [Cites] Int J Radiat Biol. 2003 Mar;79(3):211-6 [12745886.001]
  • [Cites] Immunol Rev. 2003 Aug;194:77-95 [12846809.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):695-701 [12951588.001]
  • [Cites] Mutat Res. 2003 Oct 7;540(2):153-63 [14550499.001]
  • [Cites] Rev Esp Enferm Dig. 2004 Jan;96(1):48-59 [14971997.001]
  • [Cites] Nature. 2004 Mar 4;428(6978):77-81 [14999283.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):11-27 [15000146.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2258-63 [15026371.001]
  • [Cites] IARC Sci Publ. 2004;(157):179-205 [15055296.001]
  • [Cites] Mutat Res. 1985 Feb-Apr;147(1-2):29-36 [3974610.001]
  • [Cites] Nature. 1987 Aug 13-19;328(6131):614-6 [3039373.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Science. 1991 Aug 9;253(5020):661-5 [1651562.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] Nat Genet. 1994 Mar;6(3):217-9 [8012377.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Lancet. 1997 Aug 2;350(9074):330-3 [9251638.001]
  • [Cites] Mutat Res. 1997 Aug 1;392(1-2):1-4 [9269325.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):300-3 [9521327.001]
  • [Cites] Mutat Res. 1998 Feb;410(1):81-116 [9587425.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3455-60 [9699680.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Mutat Res. 1999 Jul 16;428(1-2):271-83 [10517999.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5541-6 [15809428.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):991-9 [15705599.001]
  • [Cites] Carcinogenesis. 2006 Feb;27(2):337-43 [16123119.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2514-9 [16510566.001]
  • [Cites] Biochimie. 2006 Nov;88(11):1515-31 [16919864.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):818-22 [11221861.001]
  • (PMID = 19058310.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2773879
  •  go-up   go-down


85. Jang KS, Song YS, Jang SH, Min KW, Na W, Jang SM, Jun YJ, Lee KH, Choi D, Paik SS: Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology; 2010 Jan;56(2):229-39
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma.
  • METHODS AND RESULTS: Immunohistochemistry staining for PTEN was performed on a tissue microarray of 19 samples of normal colonic mucosa, 14 adenomatous polyps, 482 adenocarcinomas and 56 metastatic lymph nodes.
  • However, only 241 (50.0%) of the 482 colorectal adenocarcinomas and 26 (46.4%) of the 56 metastatic lymph nodes were positive for PTEN.
  • On univariate survival analysis, patients with PTEN- adenocarcinoma revealed a poor overall and disease-free survival (P = 0.030 and P = 0.046, respectively).
  • CONCLUSIONS: Nuclear PTEN expression gradually decrease during the normal-adenoma-adenocarcinoma-metastasis sequence, which suggests an important role for PTEN in carcinogenesis.
  • Moreover, loss of nuclear PTEN expression was a marker of poor clinical outcome in patients with stage II colorectal cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenomatous Polyps / metabolism. Cell Nucleus / metabolism. Colon / metabolism. Colorectal Neoplasms / metabolism. Intestinal Mucosa / metabolism. Lymph Nodes / metabolism. PTEN Phosphohydrolase / metabolism. Rectum / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20102402.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


86. Wu CM, Tang R, Wang JY, Changchien CR, Hsieh LL: Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan. Cancer Genet Cytogenet; 2005 Apr 1;158(1):55-60
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan.
  • Mutations in codons 12 and 13 of the K-RAS oncogene are detected at a remarkably high frequency in colorectal adenocarcinoma and are believed to be a critical event in oncogenesis.
  • In the present study, we evaluated colorectal tumor specimens from Taiwan for mutations in K-RAS codons 12 and 13 using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis and direct DNA sequencing.
  • The high frequency of transitions among K-RAS mutation suggests that G/T mismatches play an important role in the oncogenesis of colorectal adenocarcinoma, implying that alkylating carcinogens may be involved in the colorectal carcinogenesis.
  • The reason for these results may be that diet and ethnicity are not rate limit factors in controlling the spectra of mutations but influence on the frequency of K-RAS mutations in human colorectal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Codon. Colorectal Neoplasms / genetics. Genes, ras. Mutation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771905.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon
  •  go-up   go-down


87. Lee YY, Yu CP, Lin CK, Nieh S, Hsu KF, Chiang H, Jin JS: Expression of survivin and cortactin in colorectal adenocarcinoma: association with clinicopathological parameters. Dis Markers; 2009;26(1):9-18
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of survivin and cortactin in colorectal adenocarcinoma: association with clinicopathological parameters.
  • We tested the hypothesis that survivin and cortactin expressions correlate with the clinico-pathological parameters of colorectal adenocarcinomas and survival time.
  • METHODS: Immunohistochemical analysis of survivin and cortactin were performed using tissue microarrays of 119 specimens from 18 well, 50 moderately, and 27 poorly differentiated colorectal adenocarcinomas and 24 colorectal adenomas with dysplasia.
  • As control, 10 specimens of normal colorectal epithelia were included.
  • RESULTS: The percentage of cells immunostained and the immunostaining scores for survivin and cortactin were all significantly higher in well-, moderately, and poorly differentiated colorectal adenocarcinomas than in normal colorectal epithelia.
  • Survivin and cortactin may be good biomarkers of aggressiveness of colorectal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Cortactin / metabolism. Microtubule-Associated Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19242064.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / CTTN protein, human; 0 / Cortactin; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins
  • [Other-IDs] NLM/ PMC3833605
  •  go-up   go-down


88. Riquet M, Foucault C, Cazes A, Mitry E, Dujon A, Le Pimpec Barthes F, Médioni J, Rougier P: Pulmonary resection for metastases of colorectal adenocarcinoma. Ann Thorac Surg; 2010 Feb;89(2):375-80
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary resection for metastases of colorectal adenocarcinoma.
  • BACKGROUND: Surgery is a safe and effective treatment for patients with lung metastases from colorectal carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Colorectal Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • [CommentIn] Ann Thorac Surg. 2010 Feb;89(2):380 [20103302.001]
  • (PMID = 20103301.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


89. Ruiz-Tovar J, López Hervás P: Value of third metastasectomy of colorectal adenocarcinoma. Clin Transl Oncol; 2007 Jan;9(1):56-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of third metastasectomy of colorectal adenocarcinoma.
  • 62 year-old woman with a tumour in sigmoid colon invading left ovary and metastases in both hepatic lobes.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17272232.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


90. Kojima M, Nakamura S, Shimizu K, Iijima M, Saruki N, Sakata N, Masawa N: Usefulness of immunohistochemistry for recognizing metastatic colorectal adenocarcinoma in infarcted lymph nodes. Pathol Res Pract; 2005;200(11-12):771-4
MedlinePlus Health Information. consumer health - Lymphatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of immunohistochemistry for recognizing metastatic colorectal adenocarcinoma in infarcted lymph nodes.
  • Here, we report on the histopathologic and immunohistologic findings of three cases showing lymph node infarction in the regional lymph node associated with metastatic colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Immunohistochemistry / methods. Infarction / pathology. Lymph Nodes / blood supply. Lymphatic Diseases / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792119.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 68238-35-7 / Keratins
  •  go-up   go-down


91. Seretis E, Konstantinidou A, Arnogiannakis N, Xinopoulos D, Voloudakis-Baltatzis IE: Mucinous colorectal adenocarcinoma with signet-ring cells: immunohistochemical and ultrastructural study. Ultrastruct Pathol; 2010 Dec;34(6):337-43
Hazardous Substances Data Bank. GLUCAGON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous colorectal adenocarcinoma with signet-ring cells: immunohistochemical and ultrastructural study.
  • A primary mucinous colorectal adenocarcinoma tissue with signet-ring cells, as revealed after histological evaluation, was examined ultrastructurally.
  • Electron microscopically mucinous adenocarcinoma was characterized by the formation of small lumen.
  • Adenocarcinoma cells were full of mucous granules of varying electron density, providing a good environment for the tumor cells to grow.
  • [MeSH-major] Carcinoma, Signet Ring Cell / ultrastructure. Colorectal Neoplasms / ultrastructure. Cystadenocarcinoma, Mucinous / ultrastructure

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21070165.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins; 333DO1RDJY / Serotonin; 37221-79-7 / Vasoactive Intestinal Peptide; 51110-01-1 / Somatostatin; 9007-92-5 / Glucagon; PX9AZU7QPK / Bombesin
  •  go-up   go-down


92. Khalifa MA, Rowsell CH, Gladdy R, Ko YJ, Hanna S, Smith A, Law C: Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma? World J Surg Oncol; 2006;4:92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma?
  • BACKGROUND: There is immunohistochemical evidence to suggest that expression of epidermal growth factor receptor (EGFR) in primary colorectal adenocarcinoma predicts its expression in recurrent disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 May;6(5):2053-63 [10815932.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):903-13 [14967450.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1201-8 [14993230.001]
  • [Cites] Cancer Treat Rev. 2004 May;30(3):255-68 [15059649.001]
  • [Cites] J Histochem Cytochem. 2004 Jul;52(7):893-901 [15208356.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4772-8 [15570078.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4966-70 [15611511.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1803-10 [15677699.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1503-7 [15980160.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7480-9 [16243822.001]
  • [Cites] J Biol Chem. 1990 May 15;265(14):7709-12 [2186024.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4726-31 [3015394.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4885-92 [11156248.001]
  • (PMID = 17163999.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1705809
  •  go-up   go-down


93. Earle JS, Luthra R, Romans A, Abraham R, Ensor J, Yao H, Hamilton SR: Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn; 2010 Jul;12(4):433-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma.
  • MicroRNAs (miRNA), small noncoding RNAs, are potential diagnostic and prognostic markers, as well as therapeutic targets. miRNA profiles of colorectal carcinomas have not been studied extensively in the context of microsatellite instability (MSI) status.
  • We therefore evaluated 55 paired colorectal adenocarcinomas (CRC) and non-neoplastic mucosa samples using a panel of 24 miRNAs selected by literature review and prior studies in our laboratory.
  • Relative expression of miR-92, -223, -155, -196a, -31, and -26b were significantly different among MSI subgroups, and miR-31 and miR-223 were overexpressed in CRC of patients with hereditary non-polyposis colorectal cancer syndrome (Lynch syndrome).

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Biol. 2003 Apr 29;13(9):790-5 [12725740.001]
  • [Cites] Cell. 2003 Apr 4;113(1):25-36 [12679032.001]
  • [Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Cell. 1993 Dec 3;75(5):855-62 [8252622.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2318-24 [15800322.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Gene Ther. 2006 Mar;13(6):496-502 [16195701.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Biol Pharm Bull. 2006 May;29(5):903-6 [16651716.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2359-67 [16710035.001]
  • [Cites] Mol Cancer. 2006;5:29 [16854228.001]
  • [Cites] Oncol Rep. 2006 Oct;16(4):845-50 [16969504.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Am J Respir Cell Mol Biol. 2007 Jan;36(1):8-12 [16917074.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3432-7 [17360662.001]
  • [Cites] DNA Cell Biol. 2007 May;26(5):311-20 [17504027.001]
  • [Cites] Nat Biotechnol. 2007 Jun;25(6):631-8 [17557095.001]
  • [Cites] J Mol Diagn. 2007 Jul;9(3):281-3 [17591925.001]
  • [Cites] J Mol Diagn. 2007 Jul;9(3):305-14 [17591929.001]
  • [Cites] PLoS Genet. 2007 Aug;3(8):e146 [17784791.001]
  • [Cites] Gut. 2007 Nov;56(11):1564-71 [17339237.001]
  • [Cites] Mol Cancer. 2007;6:54 [17716371.001]
  • [Cites] J Mol Diagn. 2008 Jan;10(1):13-27 [18165277.001]
  • [Cites] JAMA. 2008 Jan 30;299(4):425-36 [18230780.001]
  • [Cites] Oncology. 2007;72(5-6):397-402 [18196926.001]
  • [Cites] Gastroenterol Clin North Am. 2008 Mar;37(1):47-72, vi [18313539.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2560-9 [18451217.001]
  • [Cites] Mol Cell Biol. 2008 Jul;28(14):4609-19 [18474618.001]
  • [Cites] J Clin Oncol. 2009 Apr 10;27(11):1814-21 [19273709.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Lancet. 2000 May 20;355(9217):1745-50 [10832824.001]
  • [Cites] Curr Opin Oncol. 2001 Jan;13(1):63-9 [11148689.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • (PMID = 20413677.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2893627
  •  go-up   go-down


94. Hauptmann S, Grünewald V, Molls D, Schmitt WD, Köbel M, Kriese K, Schürmann A: Glucose transporter GLUT1 in colorectal adenocarcinoma cell lines is inversely correlated with tumour cell proliferation. Anticancer Res; 2005 Sep-Oct;25(5):3431-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucose transporter GLUT1 in colorectal adenocarcinoma cell lines is inversely correlated with tumour cell proliferation.
  • Three kinetically different cell lines of colorectal adenocarcinomas (HRT-18, HT29 and CX-2) were used for the experiments.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Monosaccharide Transport Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101160.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glucose Transporter Type 1; 0 / Monosaccharide Transport Proteins; 0 / SLC2A1 protein, human; IY9XDZ35W2 / Glucose; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


95. Quadros CA, Lopes A, Araujo I, Fregnani JH, Fahel F: Upstaging benefits and accuracy of sentinel lymph node mapping in colorectal adenocarcinoma nodal staging. J Surg Oncol; 2008 Oct 1;98(5):324-30
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upstaging benefits and accuracy of sentinel lymph node mapping in colorectal adenocarcinoma nodal staging.
  • BACKGROUND AND OBJECTIVES: Sentinel lymph node (SLN) mapping is an additional method for improving colorectal cancer nodal staging.
  • METHODS: Lymphatic mapping was performed using technetium-99m-phytate and patent blue in 52 consecutive colorectal adenocarcinoma patients.
  • Colon tumors had an SLN identification rate of 90.9% and rectal tumors had 63.3% (P = 0.023).
  • CONCLUSIONS: Upstaging benefits of SLN mapping should be considered in colon and mid- and upper rectal tumors.
  • The method should be avoided in patients with lower rectal tumors, large tumors and having had neoadjuvant therapy.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Neoplasm Staging. Sentinel Lymph Node Biopsy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18618578.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


96. Kosugi C, Saito N, Murakami K, Ochiai A, Koda K, Ono M, Sugito M, Ito M, Oda K, Seike K, Miyazaki M: Positron emission tomography for preoperative staging in patients with locally advanced or metastatic colorectal adenocarcinoma in lymph node metastasis. Hepatogastroenterology; 2008 Mar-Apr;55(82-83):398-402
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography for preoperative staging in patients with locally advanced or metastatic colorectal adenocarcinoma in lymph node metastasis.
  • BACKGROUND/AIMS: The impact of positron emission tomography was prospectively evaluated using 18 (F)-fluoro-deoxyglucose (FDG-PET) for the detection of lymph node (LN) metastasis in preoperative locally advanced colorectal adenocarcinoma, compared with computed tomography (CT) and pathologic findings.
  • METHODOLOGY: Fifty-three patients who were suspected of LN involvement by CT were staged preoperatively for LN metastasis using FDG-PET and CT.
  • Regional LNs were classified into 3 groups, N1, N2-3, and N4, according to the Japanese General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus (6th Edition).
  • CONCLUSIONS: While FDG-PET is markedly more sensitive than CT for detection of N4 LN involve. ment, the number of metastatic LNs is difficult to determine.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radionuclide imaging. Colorectal Neoplasms / pathology. Positron-Emission Tomography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613374.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


97. Kim JC, Roh SA, Lee KH, Namgung H, Kim JR, Kim JS: Genetic and pathologic changes associated with lymphovascular invasion of colorectal adenocarcinoma. Clin Exp Metastasis; 2005;22(5):421-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and pathologic changes associated with lymphovascular invasion of colorectal adenocarcinoma.
  • Lymphovascular invasion (LVI) is a biological manifestation of aggressive behavior in colorectal cancer.
  • We consecutively recruited 81 and 79 colorectal cancer patients with and without LVI, respectively.
  • Allelic loss or MSI was examined using 10 microsatellite markers on chromosomes 10, 16, 18, and TGFbetaRII, possibly associated with colorectal cancer.
  • In summary, in a subset of colorectal cancers, histological differentiation and expression of CEA or E-cadherin appear to determine aggressive behavior such as LVI.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Cadherins / biosynthesis. Carcinoembryonic Antigen / biosynthesis. Chromosome Aberrations. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16283485.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


98. Melis M, Choi EA, Anders R, Christiansen P, Fichera A: Synchronous colorectal adenocarcinoma and gastrointestinal stromal tumor (GIST). Int J Colorectal Dis; 2007 Feb;22(2):109-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous colorectal adenocarcinoma and gastrointestinal stromal tumor (GIST).
  • We present two cases of an invasive colon cancer with a synchronous small-bowel GIST; immunohistochemistry studies were performed to evaluate possible genetic similarities.
  • METHODS: This paper reports two cases of synchronous GISTs and colorectal cancer (CRC) with immunohistochemistry analysis of c-Kit expression.
  • RESULTS: In the last 2 years, we observed two patients with synchronous CRCs and GISTs of the small bowel.
  • The GISTs were incidentally discovered during the work-up for CRCs and excised at the time of the colon resection.
  • Further studies are needed to clarify a possible role of c-Kit in the development of colonic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Gastrointestinal Stromal Tumors / genetics. Jejunal Neoplasms / genetics. Neoplasms, Multiple Primary / genetics

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639561.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 33
  •  go-up   go-down


99. Maillard P, Loock B, Grierson DS, Laville I, Blais J, Doz F, Desjardins L, Carrez D, Guerquin-Kern JL, Croisy A: In vitro phototoxicity of glycoconjugated porphyrins and chlorins in colorectal adenocarcinoma (HT29) and retinoblastoma (Y79) cell lines. Photodiagnosis Photodyn Ther; 2007 Dec;4(4):261-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro phototoxicity of glycoconjugated porphyrins and chlorins in colorectal adenocarcinoma (HT29) and retinoblastoma (Y79) cell lines.
  • METHOD: In this paper, we report about the screening of the in vitro photocytotoxicity of hydrophenylporphyrins and chlorins and their glycoconjugated derivatives in a human retinoblastoma cell line (Y79) and for comparison in a colorectal adenocarcinoma cell line (HT29).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25047563.001).
  • [ISSN] 1572-1000
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


100. Chen ZM, Ritter JH, Wang HL: Differential expression of alpha-methylacyl coenzyme A racemase in adenocarcinomas of the small and large intestines. Am J Surg Pathol; 2005 Jul;29(7):890-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of alpha-methylacyl coenzyme A racemase in adenocarcinomas of the small and large intestines.
  • Alpha-methylacyl coenzyme A racemase (AMACR), a novel immunomarker for prostatic adenocarcinoma, has recently been shown to be expressed in a number of malignancies including colorectal adenocarcinoma.
  • In the current study, 59 surgically resected primary small intestinal adenocarcinomas (34 ampullary and 25 non-ampullary) were immunohistochemically examined for AMACR expression and compared with 66 colorectal adenocarcinomas (including 24 secondary tumors involving the small intestine by direct extension or metastasis).
  • The results show that no AMACR immunoreactivity was detected in normal-appearing small and large intestinal mucosa.
  • While 41 of 66 (62%) colorectal adenocarcinomas exhibited a variable degree of cytoplasmic staining, only 1 of 25 (4%) non-ampullary and 2 of 34 (6%) ampullary small intestinal adenocarcinomas showed positive AMACR immunoreactivity (P < 0.0001).
  • Interestingly, AMACR appeared to be less frequently expressed in mucinous or poorly differentiated colorectal adenocarcinomas when compared with non-mucinous or better-differentiated counterparts, suggesting an association with microsatellite instability status.
  • These results extend our previous observations that small intestinal adenocarcinomas differ markedly from colorectal adenocarcinomas despite their morphologic similarity.
  • The different AMACR expression patterns may not only provide an additional diagnostic tool in the distinction between adenocarcinomas of the small and large intestinal origins but may also shed light on further understanding of intestinal tumorigenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Racemases and Epimerases / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958853.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down






Advertisement